Patent Grant
11541221
The present disclosure relates to medical tubing sets and methods for killing microorganisms and providing in-situ antimicrobial properties to medical devices.
Tubing sets are commonly used in providing modern medical care to patients. For example, they are a commonly used means for infusing fluids into catheters such as central venous catheters, peripherally inserted central catheters, midline catheters, hemodialysis catheters, peritoneal dialysis catheters and drainage catheters. Tubing sets are also used with other infusion devices, such as needleless connectors, valves and filters.
These tubing sets are useful for treating various medical conditions. For example, medical tubing can be used to connect an IV drip bag to an access port into the patient's body. In other uses, tubing sets allow patients with renal disease to have waste and fluid removed from their bodies, and patients in need of total parental nutrition (TPN) use tubing sets to deliver nutrients from an IV bag to a TPN catheter. Thus, tubing sets make critical medical care possible and are often essential to providing improved health care outcomes.
However, use of tubing sets has a serious drawback in that a significant percentage of patients develop infections, resulting in elevated mortality rates and significantly increased healthcare costs associated with treatment. Furthermore, infections are a leading cause of death in the United States, and many of those infections are attributable to microorganisms entering infusion devices through the tubing set connection. The mortality rate associated with such infections is considerable. Therefore, a need exists for a manner to reduce infections relating from the use of tubing sets.
Infection-causing organisms are ever present in the environment; they live on patients' skin and can survive and be transmitted in air and water. Conventional medical device connectors and caps, such as male and female connectors with tapered luers, contain a threaded region along with a tapered sealing region, such as an overlapping sealing region of the tapered portions of male and female connectors. The overlapping sealing regions seal fluid inside the medical device and keep air and organisms out. However, our testing shows that organisms can still migrate through the threaded region and penetrate a portion of the way into the sealing region. This results in organisms being present along the walls of the tapered portions of the male and female luers within a thin interstitial space of the sealing region. When the male and female connectors are separated from one another, some organisms can remain on the walls of the male and female connectors, including on tapered portions of male luer and female luer of the male and female connectors that previously formed a seal. The next time a connection is made, some of the organisms on the wall of the female luer can be pushed past the sealing surface and into the fluid path (during insertion of the male luer into the female luer). Once organisms are in the fluid path they can multiply, spread, and cause an infection.
The walls of the male luer and female luer are typically tapered, or at least partially tapered, and may also become contaminated by airborne organisms landing on the surface or through touch contamination. Upon inserting the male luer into the female luer the organisms can be pushed into the fluid path where they can also multiply, spread, and cause an infection.
Tubing sets are used to make fluid connections between medical devices, typically for infusing fluids and drugs into the body. For instance, they are commonly used to transfer fluid from saline bag to an IV catheter and ultimately the bloodstream.
In certain aspects of the subject matter described herein, the distal end of the male luer, as well as intermediate portions (portions between the distal and proximal ends) of the male luer, contain an antimicrobial composition. As used herein, the terms “proximal end” and “distal end” are used to refer to the relative positions on an article. With regard to a catheter, for example, the proximal end is the end closest to a person servicing the catheter female connector, while the distal end is closest to a patient. For example, the distal end of a hemodialysis catheter will be inside a patient, while the proximal end will be outside the patient and have a female luer on a female connector. Similarly, the proximal end of a male cap containing a male luer will be outside of the female connector when coupled to the female connector, while the distal end of the male cap will be inside the female connector when coupled to the female connector. As will be discussed later,
The present disclosure is directed, in part, to tubing sets used to form a coupling with medical device, the coupling typically comprising both a male connector and a female connector. In certain embodiments, the male connector will form a fluid tight seal with a female connector that complies with International Standard ISO 80369-7 Connectors for intravascular or hypodermic applications.
It should be appreciated that the various embodiments disclosed here may also be applied to other types of infusion devices. Examples disclosed herein include needleless connectors and caps. These examples are used to illustrate the broader application of the invention, but it should be further appreciated that the unique aspects of these embodiments may also be applied to tubing sets.
As used herein, the term “female connector” is used to refer to portions of an infusion device containing a female connector, and the female connector generally includes a truncated conical taper referred to herein as the “female luer”. The truncated conical taper forming the female luer typically has a tapered surface. The female connector also includes immediately surrounding elements, such as a threaded outer portion. The term “female connector” as used herein is also sometimes referred to interchangeably in the medical field as a “female connector”, “adapter”, “hub”, and “fitting” when describing an element containing a female luer. As used herein, the terms “male connector” and “male cap” are used to refer to connectors having a sealing extension called a male luer, and this male luer generally has a tapered surface (although in some implementations only parts of that male luer will be tapered). A male connector has a fluid flow path through it (along its axis), while a male cap is sealed and does not have a fluid flow path through it. Thus, a male connector is meant to allow fluid flow through it while a male cap is meant to form a fluid-tight seal and stop fluid flow within a catheter. In many implementations the male connector and cap will have similar or identical internal geometries, other than a central conduit for fluid flow, and in this disclosure the term “connector” is therefore sometimes used to refer to both a connector with a fluid path through it and a cap that does not have a fluid flow path through it. When describing a specific embodiment, the term “connector” or “cap” may be used to describe a specific embodiment, but this is generally not meant to be limiting.
When describing a mated pair of devices, such as a female connector combined with a male connector, the term “coupling” is used herein. Alternatively, the female connector can be combined with a male cap, which is also a “coupling” as used herein. In summary, as used herein a coupling is a female connector combined with either a male connector or a male cap. A female connector in turn is a portion of an infusion device, and the female connector contains a cavity or volume known as the female luer. This cavity or volume known as the female luer typically has a tapered interior surface. The male connector and male cap each include a sealing extension called a male luer that fits within a female luer. The male luer typically has a tapered outer sealing surface. A seal is formed when the tapered surface of the male luer on the male connector or cap contacts the tapered surface of the female luer of the female connector. When these tapered surfaces are in contact with one another the female connector and male connector or cap combine to form a coupling. This coupling can allow flow between infusion devices (such as when a female connector and male connector combine) or prevent flow (such as when a female connector and male cap combine). In both cases it is highly desirable to have the seal between the female and male luers be constructed so as to form a fluid tight seal and prevent ingress of microbes, such as bacteria and fungi.
In certain implementations described herein, the male luer of the male connector or cap delivers an antimicrobial composition to the female luer of the female connector.
In one embodiment the male luer has a distal tip near its distal end, the distal tip surface containing an antimicrobial composition. In certain implementations the male luer comprises a recess in the intermediate portion of its tapered outer sealing surface (between the proximal and distal ends of the tapered outer surface, but still on the tapered portion of the male luer), the recessed surface containing an antimicrobial composition. In certain implementations the male luer comprises a distal recessed portion (at the distal end of the male luer) and an intermediate recessed portion, with both recessed surfaces containing an antimicrobial composition. In certain implementations the male luer comprises a flat end face at its distal end. In certain implementations the male luer comprises an antimicrobial coating at the end face region. In certain implementations the male luer comprises an antimicrobial coating at a distal tip region.
Some examples herein provide a method for delivering an antimicrobial composition from a medical tubing set to a medical device, the method comprising: inserting a male connector of a medical tubing set into a female connector of an infusion device; the male connector having a male tapered surface and the female connector having a female tapered surface, such that the male tapered surface engages the female tapered surface to form a substantially fluid-tight seal, the male connector having: a distal tip having a distal end face; the distal tip having a recess surface proximal to the distal end face, wherein the recess surface is radially inward of a line of taper extending along, and distal of, the male tapered surface at a first taper angle relative to a central longitudinal axis of the male connector; and a water-soluble antimicrobial composition positioned on the recess surface; wherein, upon insertion of the male connector into the female connector, the recess surface and the female tapered surface form a cavity and a fluid at least partially fills the cavity, and wherein at least a portion of the antimicrobial composition is dispersed within the fluid in the cavity.
In some examples, the male connector further comprising a tapered surface distal edge proximal to the distal end face of the male connector. In some examples, the tapered surface distal edge being at a distalmost end of the male tapered surface. In some examples, the tapered surface distal edge is proximal to at least part of the cavity formed between the female tapered surface and the recess surface. In some examples, the tapered surface distal edge has an inner diameter, the distal tip has an outer diameter, and the inner diameter of the tapered surface distal edge is greater than the outer diameter of the distal tip. In some examples, the male connector further comprises a fluid flow channel through the male connector. In some examples, the antimicrobial composition comprises chlorhexidine. In some examples, a portion of the antimicrobial composition dissolves into the fluid and forms a chlorhexidine precipitate on a portion of the female tapered surface. In some examples, after a portion of the antimicrobial composition is dispersed within the fluid in the cavity, the dispersed antimicrobial composition retains a concentration in the cavity of at least 200 micrograms per milliliter for a time period of at least 1 hour. In some examples, the cavity defines a volume within a range of 1 microliters to 25 microliters. In some examples, a plurality of blades extend radially outward from the recess surface into the cavity to at least partially divide the cavity. In some examples, the first taper angle is equal to a second taper angle of the recess surface relative to the central longitudinal axis. In some examples, the male connector further comprises a proximal trap comprising an annular cavity at least partially opening into the cavity formed between the female tapered surface and the recess surface.
Some further examples provide a method for delivering an antimicrobial composition from a medical tubing set to a medical device, the method comprising: inserting a male connector of a medical tubing set having a male tapered surface into a female connector of an infusion device, the female connector having a female tapered surface, such that the male tapered surface engages the female tapered surface to form a fluid-tight seal, the male connector having: a conical taper defined in part by the male tapered surface; a distal tip having a distal end face, and a recess surface proximal to the distal end face and inside the conical taper; a tapered surface distal edge of the male tapered surface and proximal to the distal tip; a fluid flow channel through the male connector; a water-soluble antimicrobial composition positioned on the recess surface; wherein, upon insertion of the male connector into the female connector, an annular cavity is formed between, and at least partly defined by, the recess surface and the female tapered surface of the female connector, the annular cavity having a proximal end coincident with the tapered surface distal edge and a distal end coincident with the distal tip end face, a volume between the proximal end and the distal end, a depth measured radially, and a length measured axially; wherein the distal end of the annular cavity is in fluid communication with a fluid lumen of the infusion device, and the length of the annular cavity is at least twice the depth of the annular cavity; and wherein a fluid at least partially fills the annular cavity, and at least a portion of the antimicrobial composition is dispersed within the fluid in the annular cavity.
Some further examples provide a medical tubing set configured to deliver an antimicrobial composition to a medical device, the medical tubing set comprising: a medical tube; a male connector secured to the medical tube, the male connector having a male tapered surface, the male connector further including: a distal tip having a distal end face; a radially-outward-facing recess surface proximal to the distal end face, wherein the recess surface is radially inward of a line of taper extending along, and distal of, the male tapered surface at a first taper angle relative to a central longitudinal axis of the male connector; and a water-soluble antimicrobial composition positioned on the recess surface.
In some examples, the male connector further comprising a tapered surface distal edge proximal to the distal end face of the male connector, the tapered surface distal edge being at the distalmost end of the male tapered surface. In some examples, the tapered surface distal edge is proximal to at least part of the recess surface. In some examples, a plurality of blades extend radially outward from the recess surface and divide the recess surface. In some examples, the plurality of blades comprise a plurality of blade surfaces and at least a portion of the antimicrobial composition is located on the plurality of blade surfaces. In some examples, the male tapered surface further comprises a proximal trap comprising an annular cavity proximal to a distal end of the male tapered surface.
While embodiments are susceptible to various modifications and alternative forms, specifics thereof have been shown by way of example and drawings, and will be described in detail. It should be understood, however, that the scope herein is not limited to the particular embodiments described. On the contrary, the intention is to cover modifications, equivalents, and alternatives falling within the spirit and scope herein.
The device may be more completely understood in connection with the following drawings, in which:
It will be noted that in some cross-sectional figures the illustrations have been simplified, such as removal of the background threads on the sealing cover to make the various aspects of the invention more apparent. While embodiments are susceptible to various modifications and alternative forms, specifics thereof have been shown by way of example and drawings, and will be described in detail. It should be understood, however, that the scope herein is not limited to the particular embodiments described. On the contrary, the intention is to cover modifications, equivalents, and alternatives falling within the spirit and scope herein. For example, the term “infusion device” of
Numerous challenges are present for safely using medical devices incorporating male and female connectors. For example, medical devices such as catheters used in intravenous administration of fluids, hemodialysis, peritoneal dialysis, parenteral nutrition and chemotherapy are often worn for prolonged periods of time in the moist environment next to a patient's skin. This is an ideal environment for bacterial growth. Peripherally inserted central catheters and midline catheters will typically have dozens of connections made between a male and female luer over the course of use, and each time the device is connected it provides an opportunity for infection caused by ingress of organisms along the female luer. And every infusion device that has a female luer hub is susceptible to the fact that the interior female luer surface is not readily accessible to sanitizing wipes. Conventional sterilization methods are not able to kill microorganisms once they ingress to the female luer surface. Thus, these organisms are free to continue to ingress until reaching the bloodstream and ultimately creating a bloodstream infection. In addition, drug resistant organisms are becoming more common in hospitals and outpatient healthcare settings, which makes treatment of bloodstream infections more difficult.
Multiple ingress pathways can lead to contamination of the female luer surface. One source of female luer contamination occurs when the female luer is open, with no male luer inserted. During the time the female luer is open, it is susceptible to airborne organisms landing on the surface (such as from a person's breath or other source). Another source of female luer contamination is ingress along the threads and proximal end of the female hub, where organisms can then enter into the very small gap that exists between the proximal end of the male-female luer surfaces where the surfaces touch.
Those skilled in the art understand that organisms can ingress to the proximal end of the hub, but they are widely unaware that a gap exists between the male and female luers and that organisms can infiltrate this gap where standard cleaning procedures are ineffective. Thus, the common viewpoint is that cleaning the end of a female connector is sufficient to stop this route of organism ingress. The inventors have discovered that this is not sufficient; standard alcohol wiping/cleaning procedures are not effective at killing the organisms that enter the inside of the female luer. Once inside the female luer, organisms can be pushed by the end face of the male luer into the lumen of the female luer device.
For example, use of needleless connectors on infusion devices is common practice. The needleless connectors are typically replaced every 4-7 days, thus they are prone to contamination of the inside of the female luer, as described above, which can ultimately lead to bloodstream infection.
The technology disclosed herein provides a distal recess at the distal tip of the male luer member. The distal tip surface contains a concentrated amount of an antimicrobial composition that remains confined within the cavity between the distal tip surface of the male luer and tapered sealing surface of the female luer. Organisms inside the female luer remain within the cavity, proximal to the lumen of the male luer. Various examples provided herein create an environment that confines the antimicrobial agent near the distal end of the male luer.
Referring now to the drawings,
The male connector 101 can assume any of a number of different configurations. For example, the male connector 101 can have features similar to those disclosed in relation to one or more of the embodiments provided herein below.
During the CAPD exchange process the waste dialysis solution flows from the peritoneal cavity 12 through the catheter 10, on to the coupling 17 and transfer set 14, then through coupling 18 and finally through the lower portion of the infusion set 16 into the drain bag 15b. After the exchange process is complete, the infusion set 16 is separated at coupling 18 from transfer set 14 and the female connector of transfer set 14 is capped until the next dialysis solution exchange is initiated (not shown). Thus, in typical peritoneal dialysis the exchange process is initiated by removing a male cap from the female connector of transfer set 14 and then joining to the infusion set 16 to form coupling 18; and this process is reversed at the end of the exchange process by removing the infusion set 16 at coupling 18 and installing a new male cap.
It will be appreciated that
Referring now to
Now in reference to
As is shown in
The antimicrobial agent is typically a dry-antimicrobial, and provides an antimicrobial effect to the interior of the female connector 40, especially at the region in the vicinity of the distal recess 80 of the male luer 52, the intermediate recess 82, and the overlapping region 41 (overlap of the tapered inner sealing surface 43 of the female luer 42, and the tapered outer surface 53). When the male luer 52 of the male connector 50 is inserted into the female luer 42 of the female connector 40, the microbes 28 are pushed by the tapered surface distal edge 55 of the male luer 52 rather than the end face 54; thus the microbes 28 are concentrated within the cavity 81. The antimicrobial agent 29 may become wetted by fluid in lumens 38 and 58 as the fluid flows into the recess while connecting male connector 50 to female connector 40. However, after connection, the fluid is substantially retained within the cavity 81 even when fluid flows through the male connector 50 because the cavity 81 only has one opening (at the distal end of the distal tip). This results in a high concentration of antimicrobial agent in the fluid in the cavity 81 without substantially depleting the antimicrobial agent 29 from the male connector 50. Thus, the antimicrobial agent within the fluid is at a lethal concentration for a sufficient time to kill the microbes 28.
The proximal edge 84 of intermediate recess 82 is located proximal to the proximal end of tapered inner sealing surface 43, but can optionally be located distal to the proximal end of the tapered inner sealing surface 43 of the female luer 42. Some benefits of intermediate recess 82 as shown in
In an example embodiment, the antimicrobial agent is located along the entire tapered outer surface 53 of the male connector 50, in the recesses 80, 82 and along male connector threaded surface 39 of a male connector 50 (the male connector threaded surface 39 including the proximal most surface that is adjacent to the proximal end of the tapered outer surface 53). The flow of a fluid in the lumen 38 is stopped by activating a first clamp, valve or other flow-stopping means (not shown) located distal to the female connector 40, and flow of a fluid in the lumen 58 is stopped by activating a second clamp, valve or other flow-stopping means (not shown) located proximal to the male connector 50. Prior to connecting the male connector 50 to the female connector 40, the first and second clamps are activated to prevent fluid flow within the lumens 38, 58. After activating the clamps, and as the male luer 52 is inserted into the female luer 42, the fluid inside the lumens 38, 58 is displaced creating an outward flow of the fluid between the tapered surfaces 43, 53 and into a channel 59 located outside the female connector 40 and inside the male connector threaded surface 39. As the fluid flow contacts the antimicrobial agent, a portion of the antimicrobial agent is dissolved and incorporated into the fluid; thus creating an antimicrobial fluid. The antimicrobial fluid then flows into the channel 59 where it contacts the female connector end face 48 and the female connector threaded surface 49, which subsequently kills microbes (not shown in
In some embodiments it is desirable to apply a slowly dissolving (“time-release”) coating on top of the antimicrobial agent to delay or slow the time for the antimicrobial agent to dissolve. A time-release coating, especially when applied to distal recess 80, is advantageous for ensuring a precise dose of antimicrobial agent is available within the cavity 81 once the connectors 40, 50 have been coupled together. In another embodiment it is desirable to use an antimicrobial mixture to slow the antimicrobial mixture's dissolution rate; the antimicrobial mixture comprising the antimicrobial agent and a material that dissolves slower, such as a hydrophilic water-soluble polymer. In yet another embodiment it is desirable to use chlorhexidine base with a chlorhexidine salt (such as chlorhexidine acetate) to achieve the intended dissolution rate; thus providing a means and method to control the amount of antimicrobial agent being removed from the recesses 80, 82 and tapered outer surface 53, transferring a portion of the antimicrobial agent to the female connector end face 48 and female connector threaded surface 49, where upon drying, a portion of the antimicrobial agent remains on the female connector end face 48 and female connector threaded surface 49. The benefit is this provides a persistent antimicrobial agent along the infiltration path (as shown in
As the male luer 32 is inserted into the female luer 42 of the female connector 40, microbes are pushed by the tapered surface distal edge 55 of the male luer 32 rather than end face 34; thus the microbes are concentrated within the cavity. The antimicrobial agent in the cavity may become wetted by fluid in lumen 38 being displaced as male luer 32 is inserted into female luer 42. The fluid is substantially locked within the cavity in some embodiments because the cavity only has one opening (at the distal end of the recess) after the male luer 32 is fully inserted into the female connector 40. This results in a high concentration of antimicrobial agent in the fluid in the cavity without substantially depleting the antimicrobial agent. Thus, the antimicrobial agent within the fluid is at a lethal concentration for a sufficient time to kill the microbes and prevent ingrowth of microbes.
It will be appreciated that this is just an illustrated example, and that alternative peritoneal dialysis configurations are possible. Also, it will be appreciated that peritoneal dialysis is just one example of a use for the infusion connectors and systems disclosed herein, and that alternative uses and systems include hemodialysis catheters, peripherally inserted central catheters, midline catheters, drainage catheters, needleless connectors, intravenous (IV) administration sets, peritoneal dialysis lines, transfer set, syringes, valves and filters.
The inventors have identified that it is desirable to use only a small amount of antimicrobial for safety because it reduces patient risk in the event antimicrobial escapes into the body. The amount considered a “low dose” is different from patient to patient. For example, a chlorhexidine acetate dose of 500 μg (micrograms) or higher may be considered safe for direct injection into a 60 kilogram person's bloodstream, but a dose significantly below this level is desirable for use in neonates.
The various embodiments herein have benefit over prior art from a safety standpoint because by delivering the antimicrobial agent between the luer surfaces, only a small amount of antimicrobial agent is required to kill microbes. In the various examples provided here, an annular cavity is formed between the male luer surface and the female luer surface when the male luer is installed into a female luer. The concentration of antimicrobial agent is high but the total dose is low because the gap between the luer surfaces is very small and there is little to no fluid flow away from this region, causing loss of the antimicrobial to be very low.
In some embodiments the antimicrobial agent can be chlorhexidine acetate. A concentration of greater than 200 μg/mL (micrograms per milliliter) of chlorhexidine acetate can quickly kill most microbes, including Gram positive bacteria, Gram negative bacteria, and fungi.
In various embodiments the male luer has a recess surface (also referred to as distal tip surface) containing approximately 25 to 250 μg of chlorhexidine acetate. For example, in an embodiment, the radial depth of the recess is approximately 0.005 inches (0.127 millimeters) and the axial length is approximately 0.020 inches to 0.040 inches long (0.508 mm to 1.016 mm). The annular cavity formed between the male luer surface and the female luer surface can have a volume on the order of 1 (microliter) or 0.001 mL. If 10 μg of chlorhexidine acetate is in a 1 volume, the antimicrobial concentration is 10,000 μg/mL, which is 50 times higher than the minimum desired level of 200 μg/mL to kill microbes. This demonstrates how the invention can create very high microbe kill efficacy while at the same time providing excellent patient safety; 50 μg of chlorhexidine acetate distributed over the entire surface of the male luer is 10 times lower than the maximum total dose of 500 μg that is desired for patient safety.
In some embodiments the volume of the annular cavity is between about 1 and 10 microliters. In some embodiments, the volume of the annular cavity can fall within a range of 1 microliters to 25 microliters, or 5 microliters to 20 microliters, or 10 microliters to 15 microliters, or can be about 10 microliters. In some embodiments, the volume of the annular cavity can be greater than or equal to 1 microliters, 2 microliters, 3 microliters, 4 microliters, 5 microliters, 6 microliters, 6 microliters, 7 microliters, 8 microliters, 9 microliters, or 10 microliters. In some embodiments, the volume of the annular cavity can be less than or equal to 25 microliters, 24 microliters, 22 microliters, 20 microliters, 19 microliters, 18 microliters, 16 microliters, 14 microliters, 13 microliters, 12 microliters, or 10 microliters.
Additionally, a number of different examples of antimicrobial agents can be used with the various embodiments described herein. The antimicrobial compositions should kill and/or provide stasis of Gram-positive and Gram-negative bacteria and fungi. The agents may also have efficacy at killing organisms within an established biofilm and/or degrading the extracellular matrix of the film. However, this is not necessary for the invention to be beneficial because the invention is designed to kill organisms before they have an opportunity to form a biofilm. The antimicrobial composition can be chlorhexidine acetate, also known as chlorhexidine diacetate.
Other compounds containing chlorhexidine may be used, such as chlorhexidine free base, chlorhexidine gluconate and chlorhexidine with dyes. Chlorhexidine acetate has an advantage over chlorhexidine gluconate because the risks associated with para chloroaniline may be minimized.
Other suitable antimicrobial compositions may also be used. In general, the antimicrobials are soluble in water, they have a history of clinical use with a demonstrated safety profile, they are antibiotic-free, they can be applied onto a medical device, and they can be subsequently dissolved into a composition having an effective concentration to inhibit growth of bacterial and fungal organisms. Suitable materials include chlorhexidine, chlorhexidine salts (such as chlorhexidine acetate or chlorhexidine gluconate), tetrasodium ethylenediaminetetraacetic acid (tetrasodium EDTA), sodium citrate (yielding a concentration of 30% or higher), iodine, taurolidine, disodium EDTA, silver compounds (including silver nanoparticles and ions), silver sulfadiazine, and, triclosan. In some examples, a portion of the antimicrobial composition is dissolvable to form a chlorhexidine precipitate.
While one drug or antimicrobial composition may provide relief from a wide range of challenging organisms that could potentially lead to catheter-related bloodstream infection, two or more agents may be used to increase efficacy against a broad range of infectious organisms (bacteria and fungi).
In particular, catheter-related infections arise from three broad classes of organisms: fungi, Gram-negative bacteria, and Gram-positive bacteria. If an antimicrobial composition can be identified that would abate one or two of these types of organisms, while this would certainly be beneficial, it would leave the patient vulnerable to the remaining type(s). By pairing agents with different modes of action, infections by an increased spectrum of organisms can be prevented. This synergy would likely lead to further decreases in catheter-related morbidity and mortality, lessening the impact of the implanted catheter on the patient's quality of life. Example combinations of antimicrobial compositions are chlorhexidine acetate and EDTA, silver sulfadiazine and chlorhexidine acetate, and silver sulfadiazine and methylene blue.
In principle, antibiotics (rifampin, minocycline, etc.) can be incorporated into or onto the male luer or similar device and be as effective as non-antibiotic antimicrobials. However, continuous exposure to one antibiotic can lead to antibiotic resistant bacteria strains, for example, methicillin resistant S. aureus (MRSA). Therefore, an example embodiment uses an antimicrobial composition selected from the subset of those which are not antibiotics. If, for some reason, an antibiotic is used, the risk of developing antibiotic resistant strains of bacteria may be mitigated by preparing a second, complimentary, device containing a different antibiotic. By using the two devices in an alternating fashion with successive uses, infectious organisms that are resistant to one antibiotic may be killed by the other.
In certain implementations the antimicrobial agent comprises chlorhexidine, chlorhexidine base, chlorhexidine acetate and/or chlorhexidine gluconate. In certain implementations the antimicrobial agent is a dry coating.
In certain implementations the antimicrobial agent is water soluble at greater than 1 mg/mL. In certain implementations the agent is water soluble at greater than 10 mg/mL. In certain implementations a first antimicrobial agent is water soluble at less than 1 mg/mL and a second antimicrobial is soluble at greater than 10 mg/mL. In certain implementations the antimicrobial agent is impregnated into the luer surface. In certain implementations the antimicrobial agent is a broad-spectrum compound capable of killing Gram positive bacteria, Gram negative bacteria, and fungi. In certain implementations the antimicrobial agent is a non-antibiotic antimicrobial. In certain implementations the antimicrobial agent converts into chlorhexidine dihydrochloride in presence of saline.
In certain implementations the antimicrobial agent comprises silver or silver sulfadiazine. In certain implementations the antimicrobial agent contains more than one compound. In certain implementations the antimicrobial agent comprises chlorhexidine and silver sulfadiazine. In certain implementations the antimicrobial agent comprises the antibiotics minocycline and rifampin.
In certain implementations the antimicrobial agent is applied in a solvent-based coating process. In certain implementations the antimicrobial agent is applied in a spray process. In certain implementations the antimicrobial agent is applied in a dip process. In certain implementations the antimicrobial agent is dispersed in bulk material of an injection molding process. In certain implementations the antimicrobial agent is part of an antimicrobial solution that contains a solvent that swells the device material, which allows the antimicrobial agent to impregnate the device material, where it remains after solvent evaporates.
In another aspect described in relation to
As will be discussed further below, the male luer 1441 includes a distal recess 1451, and the distal tip 1455 has a distal tip surface 1452. The distal tip surface 1452 can include an antimicrobial agent as described above. When the male luer 1441 is installed into a female luer (not shown), a cavity is created between the tapered sealing surface of the female luer and the distal tip surface 1452 of the male luer 1441. The distal tip 1455 is recessed inside the line of taper of the tapered sealing surface 1443. As used herein, a line of taper is a representation of an imaginary conical surface defining a conical taper extending beyond the tapered surface distal edge 1461 of the male luer 1441.
In the example of
A number of example implementations will now be described in relation to
Turning now to
The male luer 1541 includes a distal tip 1555 with an end face 1504. The distal tip 1555 of the male luer 1541 is recessed from the distal line of taper of the tapered sealing member 1542.
The distal line of taper 1614 defines an outer diameter of the extension of the tapered sealing surface 1543. A distal recess 1551 is a radially recessed portion of the distal tip 1555, meaning that the distal tip surface 1552 of the distal tip 1555 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 1543. The distal recess 1551 defines a space that is between the distal line of taper 1614 and distal tip surface 1552.
The male luer 1541 includes a tapered surface distal edge 1561 that defines a proximal end of the distal tip 1555. The tapered surface distal edge 1561 is situated at the distalmost end of the tapered sealing surface 1543 such that the proximal edge of the distal tip 1555 abuts the tapered surface distal edge 1561. The tapered surface distal edge 1561 has an outer diameter, the proximal edge of the distal tip 1555 has an outer diameter, and the outer diameter of the tapered surface distal edge 1561 is greater than the outer diameter of the proximal edge of the distal tip 1555. Since the tapered surface distal edge 1561 has a larger diameter than any outer diameter along the distal tip 1555, when the male luer 1541 is inserted into a female luer, the tapered surface distal edge 1561 of the tapered sealing member 1542 is capable of capturing microbes that may have infiltrated the inner surface of the female luer. As described above in relation to
The distal recess 1551 (the space between the distal tip surface 1552 and the female luer surface, not shown) is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 1552 so that microbes are exposed to a high antimicrobial concentration. Confinement is a way to keep the antimicrobial agent within the distal recess region during use, while fluid is flowing through the lumen 1512. The structure of the distal recess 1551, which contains no through-channel for fluid flow, decreases fluid transfer between the lumen 1512 and the distal tip surface 1552.
Turning now to
The male luer 1741 includes a distal tip 1755 with an end face 1704. The distal tip 1755 of the male luer 1741 is recessed from the distal line of taper 1714 of the tapered sealing member 1742. A distal recess 1751 is formed by a recessed portion of the distal tip 1755. When the male luer 1741 is sealed against a female luer and the tapered sealing surface 1743 forms a fluid tight fit with the inside surface of the female luer, the distal tip surface 1752 of the distal tip 1755 does not make contact with the inside surface of the female luer.
The male luer 1741 includes a tapered surface distal edge 1761 that defines a proximal end of the distal tip 1755. The tapered surface distal edge 1761 is situated at the distalmost end of the tapered sealing surface 1743. When the male luer 1741 is inserted into a female luer, the tapered surface distal edge 1761 of the tapered sealing member 1742 is capable of capturing microbes that may have infiltrated the inner surface of the female luer.
In some examples, an antimicrobial agent is applied to the distal tip surface 1752 by coating, spraying, or dipping the distal tip 1755 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 1743. As described above in relation to
The male luer 1741 further includes multiple blades 1763 arrayed around the distal tip 1755 of the male luer 1741. In some examples, the blades 1763 are arranged substantially parallel to the central longitudinal axis of the male luer 1741. However, as will be described in further detail below, some embodiments can have blades that are not substantially parallel to the central longitudinal axis. Between the blades 1763 are a plurality of channels 1767. In the example of
In some examples, the distal tip 1755 has a length of about 0.060 inches (1.52 mm). The length of the distal tip 1755 is measured perpendicular to the diameter of the distal tip 1755. In some examples, the lumen 1712 has an inner diameter of about 0.065 inches (1.65 mm). In some examples, the distal tip 1755 has an outer diameter of about 0.095 inches (2.41 mm). In some examples, the wall of the distal tip 1755 has a thickness of about 0.015 inches (0.38 mm). In some examples, the tapered surface distal edge 1761 has an outer diameter of about 0.155 inches (3.94 mm).
At the apex 1764 of the blades 1763, the distal tip 1755 has an outer diameter of between about 0.148 inches and 0.152 inches. At the trough 1768 of the channels 1767, the distal tip 1755 has an outer diameter of between about 0.0118 inches and 0.0121 inches. Thus the difference in outer diameter from the trough 1768 to the apex 1764 is approximately 0.030 inches in this example. The distal tip 1755 has a tip length as shown in
During insertion of the male luer 1741 into a female luer, portions of the distal tip 1755 may come in contact with the inside surface of the female luer. The apex 1764 of each blade 1763 may come in contact with the female luer surface, but the troughs 1768 of the channels 1767 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 1761, the blades 1763 have a relatively smaller contacting surface area near the end face 1704 of the distal tip 1755. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the blades 1763 compared to the tapered surface distal edge 1761 of the male luer 1741. Thus in some situations there is a greater probability of the microbes being located at the tapered surface distal edge 1761 compared to the end face 1704. This is desirable because the concentration of antimicrobial composition will be greater (it will be at a lethal concentration to kill microbes) at the tapered surface distal edge 1761 than the end face 1704.
The channels 1767 affect confinement of microbes within the distal recess 1751 because the channels 1767 provide a restricted space in which microbes can be trapped between the distal tip surface 1752 and an inside surface of a female luer. The apex 1764 of the blades 1763 provide a maximum outer diameter of the distal tip 1755, and the troughs 1768 of the channels 1767 provide a minimum outer diameter of the distal tip 1755. Although some fluid flow between adjacent channels 1767 is possible when the male luer 1741 is coupled with a female luer, the blades 1763 provide a partial physical barrier. As seen in
Turning now to
The male luer 1841 includes a distal tip 1855 with an end face 1804. The distal tip 1855 of the male luer 1841 is recessed from the distal line of taper of the tapered sealing member 1842. A distal recess 1851 is formed by a recessed portion of the distal tip 1855. The distal tip surface 1852 of the distal tip 1855 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 1843.
The male luer 1841 includes a tapered surface distal edge 1861 that defines a proximal end of the distal tip 1855. The tapered surface distal edge 1861 is situated at the distalmost end of the tapered sealing surface 1843. In some examples, an antimicrobial agent is applied to the distal tip surface 1852 by coating, spraying, or dipping the distal tip 1855 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 1843. An antimicrobial agent on the distal tip surface 1852 of the distal tip 1855 kills microbes within the distal recess 1851 between the surface of the female luer and the distal tip surface 1852. The distal recess 1851 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 1852 so that microbes are exposed to a high antimicrobial concentration.
The male luer 1841 further includes multiple blades 1863 arrayed around the distal tip 1855 of the male luer 1841. Between the blades 1863 are a plurality of channels 1867. In the example of
During insertion of the male luer 1841 into a female luer, portions of the distal tip 1855 may come in contact with the inside surface of the female luer. The apex 1864 of each blade 1863 may come in contact with the female luer surface, but the troughs 1868 of the channels 1867 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 1861, the blades 1863 have a relatively smaller surface area near the end face 1804 of the distal tip 1855. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 1841.
The channels 1867 affect confinement of microbes within the distal recess because the channels 1867 provide a restricted space in which microbes can be trapped between the distal tip surface 1852 and an inside surface of a female luer. The apex 1864 of the blades 1863 provide a maximum outer diameter of the distal tip 1855, and the troughs 1868 of the channels 1867 provide a minimum outer diameter of the distal tip 1855. Although some fluid flow between adjacent channels 1867 is possible when the male luer 1841 is coupled with a female luer, the blades 1863 provide a partial physical barrier. As seen in
The distal tip 1855 has fourteen elongated blades 1863 that extend into the threaded cavity 1839 of the male connector 1801. The male luer 1841 of
Turning now to
The male luer 1941 includes a distal tip 1955 with an end face 1904. The distal tip 1955 of the male luer 1941 is recessed from the distal line of taper of the tapered sealing member 1942. A distal recess 1951 is formed by a recessed portion of the distal tip 1955. The distal tip surface 1952 of the distal tip 1955 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 1943.
The male luer 1941 includes a tapered surface distal edge 1961 that defines a proximal end of the distal tip 1955. In some examples, an antimicrobial agent is applied to the distal tip surface 1952 by coating, spraying, or dipping the distal tip 1955 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 1943. An antimicrobial agent on the distal tip surface 1952 of the distal tip 1955 kills microbes within the distal recess 1951 between the surface of the female luer and the distal tip surface 1952. The distal recess 1951 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 1952 so that microbes are exposed to a high antimicrobial concentration.
The male luer 1941 further includes multiple blades 1963 arrayed around the distal tip 1955 of the male luer 1941. Between the blades 1963 are a plurality of channels 1967. In the example of
During insertion of the male luer 1941 into a female luer, portions of the distal tip 1955 may come in contact with the inside surface of the female luer. The apex 1964 of each blade 1963 may come in contact with the female luer surface, but the troughs 1968 of the channels 1967 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 1961, the blades 1963 have a relatively smaller surface area near the end face 1904 of the distal tip 1955. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 1941.
The channels 1967 affect confinement of microbes within the distal recess because the channels 1967 provide a restricted space in which microbes can be trapped between the distal tip surface 1952 and an inside surface of a female luer. The apex 1964 of the blades 1963 provide a maximum outer diameter of the distal tip 1955, and the troughs 1968 of the channels 1967 provide a minimum outer diameter of the distal tip 1955. Although some fluid flow between adjacent channels 1967 is possible when the male luer 1941 is coupled with a female luer, the blades 1963 provide a partial physical barrier. As seen in
The distal tip 1955 of the male luer 1941 has six blades 1963 defining six channels 1967 with troughs 1968. In the example of
Turning now to
The male luer 2041 includes a distal tip 2055 with an end face 2004. The distal tip 2055 of the male luer 2041 is recessed from the distal line of taper of the tapered sealing member 2042. A distal recess 2051 is formed by a recessed portion of the distal tip 2055. The distal tip surface 2052 of the distal tip 2055 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 2043.
The male luer 2041 includes a tapered surface distal edge 2061 that defines a proximal end of the distal tip 2055. In some examples, an antimicrobial agent is applied to the distal tip surface 2052 by coating, spraying, or dipping the distal tip 2055 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2043. An antimicrobial agent on the distal tip surface 2052 of the distal tip 2055 kills microbes within the distal recess 2051 between the surface of the female luer and the distal tip surface 2052. The distal recess 2051 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2052 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2041 further includes multiple blades 2063 arrayed around the distal tip 2055 of the male luer 2041. Between the blades 2063 are a plurality of channels 2067. In the example of
During insertion of the male luer 2041 into a female luer, portions of the distal tip 2055 may come in contact with the inside surface of the female luer. The apex 2064 of each blade 2063 may come in contact with the female luer surface, but the troughs 2068 of the channels 2067 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2061, the blades 2063 have a relatively smaller surface area near the end face 2004 of the distal tip 2055. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2041.
The channels 2067 affect confinement of microbes within the distal recess because the channels 2067 provide a restricted space in which microbes can be trapped between the distal tip surface 2052 and an inside surface of a female luer. The apex 2064 of the blades 2063 provide a maximum outer diameter of the distal tip 2055, and the troughs 2068 of the channels 2067 provide a minimum outer diameter of the distal tip 2055. Although some fluid flow between adjacent channels 2067 is possible when the male luer 2041 is coupled with a female luer, the blades 2063 provide a partial physical barrier. As seen in
The distal tip 2055 has a plurality of blades 2063 separating a plurality of channels 2067. The blades 2063 have rounded blade tips 2082 that taper in width from the end face 1904 to the apex 2064 of the blades 2063. This structure makes the distal recess 2051 rounded at the boundary between the distal recess region and the bulk flow region when the male luer 2041 is coupled with a female luer.
Turning now to
The male luer 2141 includes a distal tip 2155 with an end face 2104. The distal tip 2155 of the male luer 2141 is recessed from the distal line of taper of the tapered sealing member 2142. A distal recess 2151 is formed by a recessed portion of the distal tip 2155. The distal tip surface 2152 of the distal tip 2155 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 2143.
The male luer 2141 includes a tapered surface distal edge 2161 that defines a proximal end of the distal tip 2155. In some examples, an antimicrobial agent is applied to the distal tip surface 2152 by coating, spraying, or dipping the distal tip 2155 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2143. An antimicrobial agent on the distal tip surface 2152 of the distal tip 2155 kills microbes within the distal recess 2151 between the surface of the female luer and the distal tip surface 2152. The distal recess 2151 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2152 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2141 further includes multiple blades 2163 arrayed around the distal tip 2155 of the male luer 2141. Between the blades 2163 are a plurality of channels 2167. In the example of
During insertion of the male luer 2141 into a female luer, portions of the distal tip 2155 may come in contact with the inside surface of the female luer. The apex 2164 of each blade 2163 may come in contact with the female luer surface, but the troughs 2168 of the channels 2167 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2161, the blades 2163 have a relatively smaller surface area near the end face 2104 of the distal tip 2155. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2141.
The channels 2167 affect confinement of microbes within the distal recess because the channels 2167 provide a restricted space in which microbes can be trapped between the distal tip surface 2152 and an inside surface of a female luer. The apex 2164 of the blades 2163 provide a maximum outer diameter of the distal tip 2155, and the troughs 2168 of the channels 2167 provide a minimum outer diameter of the distal tip 2155. Although some fluid flow between adjacent channels 2167 is possible when the male luer 2141 is coupled with a female luer, the blades 2163 provide a partial physical barrier. As seen in
The distal tip 2155 has a plurality of blades 2163 that separate a plurality of channels 2167. This example shows a large difference in height from the apex 2164 to the trough 2168. This in turn increases the surface area on which an antimicrobial agent can be stored. Furthermore, the depth of the channels 2167 allows an increased load of antimicrobial agent to be stored at the distal tip 2155.
Turning now to
The male luer 2241 includes a distal tip 2255 with an end face 2204. The distal tip 2255 of the male luer 2241 is recessed from the distal line of taper of the tapered sealing member 2242. A distal recess 2251 is formed by a recessed portion of the distal tip 2255. The distal tip surface 2252 of the distal tip 2255 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 2243.
The male luer 2241 includes a tapered surface distal edge 2261 that defines a proximal end of the distal tip 2255. In some examples, an antimicrobial agent is applied to the distal tip surface 2252 by coating, spraying, or dipping the distal tip 2255 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2243. An antimicrobial agent on the distal tip surface 2252 of the distal tip 2255 kills microbes within the distal recess 2251 between the surface of the female luer and the distal tip surface 2252. The distal recess 2251 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2252 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2241 further includes multiple blades 2263 arrayed around the distal tip 2255 of the male luer 2241. Between the blades 2263 are a plurality of channels 2267. In the example of
During insertion of the male luer 2241 into a female luer, portions of the distal tip 2255 may come in contact with the inside surface of the female luer. The apex 2264 of each high blade 2265 may come in contact with the female luer surface, but the troughs 2268 of the channels 2267 and low blades 2266 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2261, the high blades 2265 have a relatively smaller surface area near the end face 2204 of the distal tip 2255. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2241.
The channels 2267 affect confinement of microbes within the distal recess because the channels 2267 provide a restricted space in which microbes can be trapped between the distal tip surface 2252 and an inside surface of a female luer. The apex 2264 of the blades 2263 provide a maximum outer diameter of the distal tip 2255, and the troughs 2268 of the channels 2267 provide a minimum outer diameter of the distal tip 2255. Although some fluid flow between adjacent channels 2267 is possible when the male luer 2241 is coupled with a female luer, the blades 2263 provide a partial physical barrier. As seen in
The distal tip 2255 has a plurality of blades 2263 that separate a plurality of channels 2267. In this example, the distal tip 2255 includes high blades 2265 and low blades 2266. The high blades 2265 have a greater outer diameter than the outer diameter of the low blades 2266. In this example, the troughs 2268 of the channels 2267 each have the same outer diameter. As can be seen in
Turning now to
The male luer 2341 includes a tapered surface distal edge 2361 that defines a proximal end of the distal tip 2355. In some examples, an antimicrobial agent is applied to the distal tip surface 2352 by coating, spraying, or dipping the distal tip 2355 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2343. An antimicrobial agent on the distal tip surface 2352 of the distal tip 2355 kills microbes within the distal recess 2351 between the surface of the female luer and the distal tip surface 2352. The distal recess 2351 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2352 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2341 further includes multiple blades 2363 arrayed around the distal tip 2355 of the male luer 2341. Between the blades 2363 are a plurality of channels 2367. In the example of
The distal tip 2355 has a plurality of blades 2363 that separate a plurality of channels 2367. In this example, the distal tip 2355 includes high blades 2365 and low blades 2366. The high blades 2365 have a greater outer diameter than the outer diameter of the low blades 2366. As seen in
During insertion of the male luer 2341 into a female luer, portions of the distal tip 2355 may come in contact with the inside surface of the female luer. The apex 2364 of each high blade 2365 may come in contact with the female luer surface, but the troughs 2368 of the channels 2367 and low blades 2366 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2361, the high blades 2365 have a relatively smaller surface area near the end face 2304 of the distal tip 2355. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2341.
The channels 2367 affect confinement of microbes within the distal recess because the channels 2367 provide a restricted space in which microbes can be trapped between the distal tip surface 2352 and an inside surface of a female luer. The apex 2364 of the blades 2363 provide a maximum outer diameter of the distal tip 2355, and the troughs 2368 of the channels 2367 provide a minimum outer diameter of the distal tip 2355. Although some fluid flow between adjacent channels 2367 is possible when the male luer 2341 is coupled with a female luer, the blades 2363 provide a partial physical barrier. As seen in
Turning now to
The male luer 2441 includes a distal tip 2455 with an end face 2404. The distal tip 2455 of the male luer 2441 is recessed from the distal line of taper of the tapered sealing member 2442. A distal recess 2451 is formed by a recessed portion of the distal tip 2455. The distal tip surface 2452 of the distal tip 2455 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 2443.
The male luer 2441 includes a tapered surface distal edge 2461 that defines a proximal end of the distal tip 2455. In some examples, an antimicrobial agent is applied to the distal tip surface 2452 by coating, spraying, or dipping the distal tip 2455 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2443. An antimicrobial agent on the distal tip surface 2452 of the distal tip 2455 kills microbes within the distal recess 2451 between the surface of the female luer and the distal tip surface 2452. The distal recess 2451 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2452 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2441 further includes multiple blades 2463 arrayed around the distal tip 2455 of the male luer 2441. Between the blades 2463 are a plurality of channels 2467. In the example of
During insertion of the male luer 2441 into a female luer, portions of the distal tip 2455 may come in contact with the inside surface of the female luer. The apex 2464 of each blade 2463 may come in contact with the female luer surface, but the troughs 2468 of the channels 2467 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2461, the blades 2463 have a relatively smaller surface area near the end face 2404 of the distal tip 2455. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2441.
The channels 2467 affect confinement of microbes within the distal recess because the channels 2467 provide a restricted space in which microbes can be trapped between the distal tip surface 2452 and an inside surface of a female luer. The apex 2464 of the blades 2463 provide a maximum outer diameter of the distal tip 2455, and the troughs 2468 of the channels 2467 provide a minimum outer diameter of the distal tip 2455. Although some fluid flow between adjacent channels 2467 is possible when the male luer 2441 is coupled with a female luer, the blades 2463 provide a partial physical barrier. As seen in
The distal tip 2455 has a plurality of blades 2463 separating a plurality of channels 2467. The blades 2463 have an apex 2464, and the channels 2467 have troughs 2468. In this example, the outer diameter of the apex 2464 is uniform, but the width of the blades 2463 increases toward the end face 2404 of the distal tip 2455. The outer diameter of the troughs 2468 decreases from the proximal portion to the distal portion of the distal tip 2455, causing the taper in the trough 2468 seen in
Turning now to
The male luer 2541 includes a distal tip 2555 with an end face 2504. The distal tip 2555 of the male luer 2541 is recessed from the distal line of taper of the tapered sealing member 2542. A distal recess 2551 is formed by a recessed portion of the distal tip 2555. The distal tip surface 2552 of the distal tip 2555 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 2543.
The male luer 2541 includes a tapered surface distal edge 2561 that defines a proximal end of the distal tip 2555. In some examples, an antimicrobial agent is applied to the distal tip surface 2552 by coating, spraying, or dipping the distal tip 2555 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2543. An antimicrobial agent on the distal tip surface 2552 of the distal tip 2555 kills microbes within the distal recess 2551 between the surface of the female luer and the distal tip surface 2552. The distal recess 2551 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2552 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2541 further includes multiple blades 2563 arrayed around the distal tip 2555 of the male luer 2541. Between the blades 2563 are a plurality of channels 2567. In the example of
During insertion of the male luer 2541 into a female luer, portions of the distal tip 2555 may come in contact with the inside surface of the female luer. The apex 2564 of each blade 2563 may come in contact with the female luer surface, but the troughs 2568 of the channels 2567 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2561, the blades 2563 have a relatively smaller surface area near the end face 2504 of the distal tip 2555. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2541.
The channels 2567 affect confinement of microbes within the distal recess because the channels 2567 provide a restricted space in which microbes can be trapped between the distal tip surface 2552 and an inside surface of a female luer. The apex 2564 of the blades 2563 provide a maximum outer diameter of the distal tip 2555, and the troughs 2568 of the channels 2567 provide a minimum outer diameter of the distal tip 2555. Although some fluid flow between adjacent channels 2567 is possible when the male luer 2541 is coupled with a female luer, the blades 2563 provide a partial physical barrier. As seen in
The distal tip 2555 has a plurality of blades 2563 separating a plurality of channels 2567. In this example, both the apex 2564 of the blades 2563 and the troughs 2568 of the channels 2567 are tapered such that the outer diameter decreases toward the end face 2504 of the distal tip 2555.
Turning now to
The male luer 2641 includes a distal tip 2655 with an end face 2604. The distal tip 2655 of the male luer 2641 is recessed from the distal line of taper of the tapered sealing member 2642. A distal recess 2651 is formed by a recessed portion of the distal tip 2655. The distal tip surface 2652 of the distal tip 2655 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 2643.
The male luer 2641 includes a tapered surface distal edge 2661 that defines a proximal end of the distal tip 2655. In some examples, an antimicrobial agent is applied to the distal tip surface 2652 by coating, spraying, or dipping the distal tip 2655 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2643. An antimicrobial agent on the distal tip surface 2652 of the distal tip 2655 kills microbes within the distal recess 2651 between the surface of the female luer and the distal tip surface 2652. The distal recess 2651 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2652 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2641 further includes multiple blades 2663 arrayed around the distal tip 2655 of the male luer 2641. Between the blades 2663 are a plurality of channels 2667. In the example of
During insertion of the male luer 2641 into a female luer, portions of the distal tip 2655 may come in contact with the inside surface of the female luer. The apex 2664 of each blade 2663 may come in contact with the female luer surface, but the troughs 2668 of the channels 2667 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2661, the blades 2663 have a relatively smaller surface area near the end face 2604 of the distal tip 2655. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2641.
The channels 2667 affect confinement of microbes within the distal recess because the channels 2667 provide a restricted space in which microbes can be trapped between the distal tip surface 2652 and an inside surface of a female luer. The apex 2664 of the blades 2663 provide a maximum outer diameter of the distal tip 2655, and the troughs 2668 of the channels 2667 provide a minimum outer diameter of the distal tip 2655. Although some fluid flow between adjacent channels 2667 is possible when the male luer 2641 is coupled with a female luer, the blades 2663 provide a partial physical barrier. As seen in
The distal tip 2655 has a plurality of blades 2663 separating a plurality of channels 2667. In this example, the base of the blades 2663 are wide at a proximal end of the distal tip 2655 and gradually taper such that the blades 2663 are narrow at a distal end of the distal tip 2655. Conversely, the channels 2667 are narrow at the proximal end and widen toward the distal end of the distal tip 2655. In some examples, the blades 2663 include a bevel 2669 at the distal end.
Turning now to
The male luer 2741 includes a distal tip 2755 with an end face 2704. The distal tip 2755 of the male luer 2741 is recessed from the distal line of taper of the tapered sealing member 2742. A distal recess 2751 is formed by a recessed portion of the distal tip 2755. The distal tip surface 2752 of the distal tip 2755 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 2743.
The male luer 2741 includes a tapered surface distal edge 2761 that defines a proximal end of the distal tip 2755. In some examples, an antimicrobial agent is applied to the distal tip surface 2752 by coating, spraying, or dipping the distal tip 2755 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2743. An antimicrobial agent on the distal tip surface 2752 of the distal tip 2755 kills microbes within the distal recess 2751 between the surface of the female luer and the distal tip surface 2752. The distal recess 2751 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2752 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2741 further includes multiple blades 2763 arrayed around the distal tip 2755 of the male luer 2741. Between the blades 2763 are a plurality of channels 2767. In the example of
During insertion of the male luer 2741 into a female luer, portions of the distal tip 2755 may come in contact with the inside surface of the female luer. The apex 2764 of each blade 2763 may come in contact with the female luer surface, but the troughs 2768 of the channels 2767 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2761, the blades 2763 have a relatively smaller surface area near the end face 2704 of the distal tip 2755. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2741.
The channels 2767 affect confinement of microbes within the distal recess because the channels 2767 provide a restricted space in which microbes can be trapped between the distal tip surface 2752 and an inside surface of a female luer. The apex 2764 of the blades 2763 provide a maximum outer diameter of the distal tip 2755, and the troughs 2768 of the channels 2767 provide a minimum outer diameter of the distal tip 2755. Although some fluid flow between adjacent channels 2767 is possible when the male luer 2741 is coupled with a female luer, the blades 2763 provide a partial physical barrier. As seen in
In this example, the distal tip 2755 includes a plurality of elongated blades 2765 and a plurality of truncated blades 2766.
Turning now to
The male luer 2841 includes a distal tip 2855 with an end face 2804. As seen in
The male luer 2841 includes a tapered surface distal edge 2861 that defines a proximal end of the distal tip 2855. In some examples, an antimicrobial agent is applied to the distal tip surface 2852 by coating, spraying, or dipping the distal tip 2855 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2843. An antimicrobial agent on the distal tip surface 2852 of the distal tip 2855 kills microbes captured between the surface of the female luer and the distal tip surface 2852. The distal recess 2851 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2852 so that microbes are exposed to a high antimicrobial concentration.
The male luer 2841 further includes multiple blades 2863 arrayed around the distal tip 2855 of the male luer 2841. Between the blades 2863 are a plurality of channels 2867. In the example of
During insertion of the male luer 2841 into a female luer, portions of the distal tip 2855 may come in contact with the inside surface of the female luer. The apex 2864 of each blade 2863 may come in contact with the female luer surface, but the troughs 2868 of the channels 2867 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 2861, the blades 2863 have a relatively smaller surface area near the end face 2804 of the distal tip 2855. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 2841.
The channels 2867 affect confinement of microbes within the distal recess because the channels 2867 provide a restricted space in which microbes can be trapped between the distal tip surface 2852 and an inside surface of a female luer. The apex 2864 of the blades 2863 provide a maximum outer diameter of the distal tip 2855, and the troughs 2868 of the channels 2867 provide a minimum outer diameter of the distal tip 2855. The blades 2863 provide a physical barrier between adjacent channels 2867 when the male luer 2841 is mated with a female luer. As seen in
In this example, the apex 2864 of each blade 2863 has an outer diameter that follows the line of taper of the tapered sealing member 2842. When the male connector 2801 is coupled with a female connector such that the male and female luers form a fluid tight fit, the apex 2864 of each blade 2863 contacts the inner surface of the female luer.
The distal tip 2855 includes a distal recess 2851. In this example, the distal recess is present inside of the volume of the channels 2867 created between the blades 2863, where the outer diameter of the distal tip 2855 is inside the line of taper of the tapered sealing member 2842.
Turning now to
The male luer 2941 includes a distal tip 2955 with an end face 2904. As seen in
The male luer 2941 includes a tapered surface distal edge 2961 that defines a proximal end of the distal tip 2955. In some examples, an antimicrobial agent is applied to the distal tip surface 2952 by coating, spraying, or dipping the distal tip 2955 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 2943. An antimicrobial agent on the distal tip surface 2952 of the distal tip 2955 kills microbes captured between the surface of the female luer and the distal tip surface 2952. The distal recess 2951 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 2952 so that microbes are exposed to a high antimicrobial concentration.
An antimicrobial agent on the distal tip surface 2952 can be stored within the volumes between the blades 2963.
The distal tip 2955 includes a plurality of blades 2963 that separate a plurality of channels 2967. The blades 2963 spiral around the axis of the lumen 2912, and the troughs 2968 of the channels 2967 follow the spiral. In this example, the apex 2964 of each blade 2963 has an outer diameter that follows the line of taper of the tapered sealing member 2942. Thus, when the male connector 2901 is coupled with a female connector such that the male and female luers form a fluid tight fit, the apex 2964 of each blade 2963 contacts the inner surface of the female luer.
In some examples, the blades 2963 have a threaded pitch that is the same as the pitch of the threads 2902 inside of the male connector 2901. Rotating the male connector 2901 around the axis of the lumen 2912 when inserting the male luer 2941 into a female luer causes the blades 2963 to rotate along with the male luer 2941. From the perspective shown in
The distal tip 2955 includes a distal recess 2951. In this example, the distal recess 2951 is present inside of the volume of the channels 2967 created between the blades 2963. As noted above, the leading edge 2981 can act as a ramp to push particles in a proximal direction, away from the end face 2904 of the distal tip 2955. An antimicrobial agent present on the distal tip surface 2952 of the distal tip 2955 can be dispersed inside the channels 2967 that form the distal recess 2951.
The channels 2967 affect confinement of microbes within the distal recess 2951 because the channels 2967 provide a restricted space in which microbes can be trapped between the distal tip surface 2952 and an inside surface of a female luer. The apex 2964 of the blades 2963 provide a maximum outer diameter of the distal tip 2955, and the troughs 2968 of the channels 2967 provide a minimum outer diameter of the distal tip 2955. The blades 2963 provide a physical barrier between adjacent channels 2967 when the male luer 2941 is mated with a female luer. The outer diameter of the distal tip 2955 is the same as the outer diameter of the tapered sealing member 2942 at the apex 2964 of the blades 2963. As seen in
Turning now to
The male luer 3041 includes a distal tip 3055 with an end face 3004. The distal tip 3055 of the male luer 3041 is recessed from the distal line of taper of the tapered sealing member 3042. A distal recess 3051 is formed by a recessed portion of the distal tip 3055. The distal tip surface 3052 of the distal tip 3055 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 3043.
In some examples, an antimicrobial agent is applied to the distal tip surface 3052 by coating, spraying, or dipping the distal tip 3055 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 3043. An antimicrobial agent on the distal tip surface 3052 of the distal tip 3055 kills microbes within the distal recess 3051 between the surface of the female luer and the distal tip surface 3052. The distal recess 3051 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 3052 so that microbes are exposed to a high antimicrobial concentration.
The distal recess 3051 affects confinement of microbes because the distal recess 3051 provides a restricted space in which microbes can be trapped between the distal tip surface 3052 and an inside surface of a female luer. As seen in
The distal tip 3055 has a distal tip surface 3052 and a distal recess 3051. In this example, the distal tip surface 3052 does not include blades. The male luer 3041 has a tapered surface distal edge 3061 at a distal end of the tapered sealing member 3042. The tapered surface distal edge 3061 has a tapered surface distal edge face 3062. A proximal trap 3071 is defined between the distal tip surface 3052 and the proximal trap walls 3073. The proximal trap 3071 is a cavity that is bounded on multiple sides. The proximal trap 3071 opens on the distal recess 3051. The proximal trap is adjacent to the tapered surface distal edge face 3062. As will be discussed below in relation to
The proximal trap 3071 stores an antimicrobial agent within the annular cavity defined by the proximal trap 3071. In some examples, microbes reside near the interface between the tapered surface distal edge 3061 and a surface of a female luer. The antimicrobial agent stored in the proximal trap 3071 ensures that the concentration of the antimicrobial agent remains high (up to the level of saturation) in the vicinity of microbes.
Both the proximal trap 3071 and the distal recess 3051 are designed to minimize washout of the antimicrobial agent from the volume created between the female luer surface and the distal tip surface 3052. The proximal trap 3071 has no separate entrance and exit. The antimicrobial agent on the surface of the proximal trap wall 3073 will diffuse out of the proximal trap 3071 after the male luer 3041 has been installed inside a female luer. There are differences between confinement of microbes and washout of the antimicrobial agent from the distal recess 3051. Confinement keeps the antimicrobial agent within the distal recess 3051 while fluid flows through the lumen 3012. Washout refers to preventing the antimicrobial agent from being washed away from the distal recess 3051 into the lumen of the female luer while the male connector is coupled with the female connector. The proximal trap 3071 prevents or minimizes fluid flow within the volume of the proximal trap 3071 because there is no through path to the body of the female luer lumen. Therefore, the antimicrobial agent is not readily washed away from the proximal trap 3071.
In some embodiments, the proximal trap depth A can be greater than or equal to 0.10 mm, 0.15 mm, 0.20 mm, 0.25 mm, 0.30 mm, 0.35 mm, 0.40 mm, or 0.45 mm. In some embodiments, the proximal trap depth A can be less than or equal to 0.80 mm, 0.75 mm, 0.70 mm, 0.65 mm, 0.60 mm, 0.55 mm, 0.50 mm, or 0.45 mm. In some embodiments, the proximal trap depth A can fall within a range of 0.10 mm to 0.80 mm, or 0.15 mm to 0.75 mm, or 0.20 mm to 0.70 mm, or 0.25 mm to 0.65 mm, or 0.30 mm to 0.60 mm, or 0.35 mm to 0.55 mm, or 0.40 mm to 0.50 mm, or can be about 0.39 mm.
The distal recess depth B is greater than the proximal trap depth A. In some embodiments, the distal recess depth B can be greater than or equal to 0.20 mm, 0.26 mm, 0.31 mm, 0.37 mm, 0.42 mm, 0.48 mm, 0.54 mm, 0.59 mm, or 0.65 mm. In some embodiments, the distal recess depth B can be less than or equal to 1.00 mm, 0.96 mm, 0.91 mm, 0.87 mm, 0.82 mm, 0.78 mm, 0.74 mm, 0.69 mm, or 0.65 mm. In some embodiments, the distal recess depth B can fall within a range of 0.20 mm to 1.00 mm, or 0.26 mm to 0.96 mm, or 0.31 mm to 0.91 mm, or 0.37 mm to 0.87 mm, or 0.42 mm to 0.82 mm, or 0.48 mm to 0.78 mm, or 0.54 mm to 0.74 mm, or 0.59 mm to 0.69 mm, or can be about 0.77 mm.
The distal recess depth B affects the depth of the cavity formed between the distal tip surface and the female tapered surface when the male luer is coupled with a female luer. In some embodiments, the distal tip can have an outer diameter that is less than 95 percent of an inner diameter of the female tapered surface at a point radially outward of the distal tip. In some embodiments, the distal tip can have an outer diameter that is between 50 percent and 95 percent of the inner diameter of the female tapered surface. In some embodiments, the outer diameter of the distal tip expressed as a percentage of the inner diameter of the female tapered surface can be greater than or equal to 50%, 55%, 60%, 65%, 70%, 75%, or 80% of the inner diameter of the female tapered surface. In some embodiments, the outer diameter of the distal tip expressed as a percentage of the inner diameter of the female tapered surface can be less than or equal to 95%, 90%, 85%, or 80% of the inner diameter of the female tapered surface. In some embodiments, the outer diameter of the distal tip expressed as a percentage of the inner diameter of the female tapered surface can fall within a range of 50% to 95%, or 55% to 90%, or 60% to 90%, or 65% to 85%, or 70% to 85%, or 70% to 80%, or 75% to 85%, or can be about 80% of the inner diameter of the female tapered surface. Various alternatives are possible based on particular applications of the technology.
Additionally, in examples where the distal tip includes blades (such as in the example of
In examples where the apex of the blade has an outer diameter equal to the inner diameter of the female tapered surface (such as in the example of
In some embodiments, the proximal trap width C can be greater than or equal to 0.10 mm, 0.18 mm, 0.26 mm, 0.34 mm, 0.41 mm, 0.49 mm, 0.57 mm, 0.65 mm, 0.73 mm, 0.81 mm, 0.89 mm, 0.96 mm, 1.04 mm, 1.12 mm, or 1.20 mm. In some embodiments, the proximal trap width C can be less than or equal to 2.50 mm, 2.41 mm, 2.31 mm, 2.22 mm, 2.13 mm, 2.04 mm, 1.94 mm, 1.85 mm, 1.76 mm, 1.66 mm, 1.57 mm, 1.48 mm, 1.39 mm, 1.29 mm, or 1.20 mm. In some embodiments, the proximal trap width C can fall within a range of 0.10 mm to 2.50 mm, or 0.18 mm to 2.41 mm, or 0.26 mm to 2.31 mm, or 0.34 mm to 2.22 mm, or 0.41 mm to 2.13 mm, or 0.49 mm to 2.04 mm, or 0.57 mm to 1.94 mm, or 0.65 mm to 1.85 mm, or 0.73 mm to 1.76 mm, or 0.81 mm to 1.66 mm, or 0.89 mm to 1.57 mm, or 0.96 mm to 1.48 mm, or 1.04 mm to 1.39 mm, or 1.12 mm to 1.29 mm, or can be about 0.51 mm.
The distal tip width D may be larger than the proximal trap width C, but could alternatively be equal to or smaller than the proximal trap width C. In some embodiments, the distal tip width D can be greater than or equal to 0.10 mm, 0.30 mm, 0.50 mm, 0.70 mm, 0.90 mm, 1.10 mm, 1.30 mm, 1.50 mm, 1.70 mm, 1.90 mm, or 2.10 mm. In some embodiments, the distal tip width D can be less than or equal to 4.00 mm, 3.81 mm, 3.62 mm, 3.43 mm, 3.24 mm, 3.05 mm, 2.86 mm, 2.67 mm, 2.48 mm, 2.29 mm, or 2.10 mm. In some embodiments, the distal tip width D can fall within a range of 0.10 mm to 4.00 mm, or 0.30 mm to 3.81 mm, or 0.50 mm to 3.62 mm, or 0.70 mm to 3.43 mm, or 0.90 mm to 3.24 mm, or 1.10 mm to 3.05 mm, or 1.30 mm to 2.86 mm, or 1.50 mm to 2.67 mm, or 1.70 mm to 2.48 mm, or 1.90 mm to 2.29 mm, or can be about 2.41 mm.
The tapered sealing member 3042 has a wall thickness E. In some embodiments, the tapered sealing member wall thickness E can be greater than or equal to 0.10 mm, 0.15 mm, 0.20 mm, 0.25 mm, 0.30 mm, 0.35 mm, 0.40 mm, or 0.45 mm. In some embodiments, the tapered sealing member wall thickness E can be less than or equal to 0.80 mm, 0.75 mm, 0.70 mm, 0.65 mm, 0.60 mm, 0.55 mm, 0.50 mm, or 0.45 mm. In some embodiments, the tapered sealing member wall thickness E can fall within a range of 0.10 mm to 0.80 mm, or 0.15 mm to 0.75 mm, or 0.20 mm to 0.70 mm, or 0.25 mm to 0.65 mm, or 0.30 mm to 0.60 mm, or 0.35 mm to 0.55 mm, or 0.40 mm to 0.50 mm, or can be about 0.39 mm.
The lumen 3012 has an inner diameter F. In some embodiments, the lumen inner diameter F can be greater than or equal to 1.00 mm, 1.13 mm, 1.26 mm, 1.39 mm, 1.52 mm, or 1.65 mm. In some embodiments, the lumen inner diameter F can be less than or equal to 2.00 mm, 1.93 mm, 1.86 mm, 1.79 mm, 1.72 mm, or 1.65 mm. In some embodiments, the lumen inner diameter F can fall within a range of 1.00 mm to 2.00 mm, or 1.13 mm to 1.93 mm, or 1.26 mm to 1.86 mm, or 1.39 mm to 1.79 mm, or 1.52 mm to 1.72 mm, or can be about 1.65 mm.
Turning now to
The male luer 3141 includes a distal tip 3155 with an end face 3104. The distal tip 3155 of the male luer 3141 is recessed from the distal line of taper of the tapered sealing member 3142. A distal recess 3151 is formed by a recessed portion of the distal tip 3155. The distal tip surface 3152 of the distal tip 3155 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 3143.
In some examples, an antimicrobial agent is applied to the distal tip surface 3152 by coating, spraying, or dipping the distal tip 3155 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 3143. An antimicrobial agent on the distal tip surface 3152 of the distal tip 3155 kills microbes within the distal recess 3151 between the surface of the female luer and the distal tip surface 3152. The distal recess 3151 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 3152 so that microbes are exposed to a high antimicrobial concentration.
The distal recess 3151 affects confinement of microbes because the distal recess 3151 provides a restricted space in which microbes can be trapped between the distal tip surface 3152 and an inside surface of a female luer. As seen in
Like the example of
Turning now to
The male luer 3241 includes a distal tip 3255 with an end face 3204. The distal tip 3255 of the male luer 3241 is recessed from the distal line of taper of the tapered sealing member 3242. A distal recess 3251 is formed by a recessed portion of the distal tip 3255. The distal tip surface 3252 of the distal tip 3255 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 3243.
The male luer 3241 includes a tapered surface distal edge 3261 that defines a proximal end of the distal tip 3255. In some examples, an antimicrobial agent is applied to the distal tip surface 3252 by coating, spraying, or dipping the distal tip 3255 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 3243. An antimicrobial agent on the distal tip surface 3252 of the distal tip 3255 kills microbes within the distal recess 3251 between the surface of the female luer and the distal tip surface 3252. The distal recess 3251 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 3252 so that microbes are exposed to a high antimicrobial concentration.
The male luer 3241 further includes multiple blades 3263 arrayed around the distal tip 3255 of the male luer 3241. Between the blades 3263 are a plurality of channels 3267. In the example of
During insertion of the male luer 3241 into a female luer, portions of the distal tip 3255 may come in contact with the inside surface of the female luer. The apex 3264 of each blade 3263 may come in contact with the female luer surface, but the troughs 3268 of the channels 3267 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 3261, the blades 3263 have a relatively smaller surface area near the end face 3204 of the distal tip 3255. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 3241.
The channels 3267 affect confinement of microbes within the distal recess because the channels 3267 provide a restricted space in which microbes can be trapped between the distal tip surface 3252 and an inside surface of a female luer. The apex 3264 of the blades 3263 provide a maximum outer diameter of the distal tip 3255, and the troughs 3268 of the channels 3267 provide a minimum outer diameter of the distal tip 3255. Although some fluid flow between adjacent channels 3267 is possible when the male luer 3241 is coupled with a female luer, the blades 3263 provide a partial physical barrier. As seen in
The male luer 3241 includes a tapered surface distal edge 3261 having a tapered surface distal edge face 3262. Like this example of
Turning now to
The male luer 3341 includes a distal tip 3355 with an end face 3304. The distal tip 3355 of the male luer 3341 is recessed from the distal line of taper of the tapered sealing member 3342. A distal recess 3351 is formed by a recessed portion of the distal tip 3355. The distal tip surface 3352 of the distal tip 3355 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 3343.
The male luer 3341 includes a tapered surface distal edge 3361 that defines a proximal end of the distal tip 3355. In some examples, an antimicrobial agent is applied to the distal tip surface 3352 by coating, spraying, or dipping the distal tip 3355 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 3343. An antimicrobial agent on the distal tip surface 3352 of the distal tip 3355 kills microbes within the distal recess 3351 between the surface of the female luer and the distal tip surface 3352. The distal recess 3351 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 3352 so that microbes are exposed to a high antimicrobial concentration.
The male luer 3341 further includes multiple blades 3363 arrayed around the distal tip 3355 of the male luer 3341. Between the blades 3363 are a plurality of channels 3367. In the example of
During insertion of the male luer 3341 into a female luer, portions of the distal tip 3355 may come in contact with the inside surface of the female luer. The apex 3364 of each blade 3363 may come in contact with the female luer surface, but the troughs 3368 of the channels 3367 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 3361, the blades 3363 have a relatively smaller surface area near the end face 3304 of the distal tip 3355. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 3341.
The channels 3367 affect confinement of microbes within the distal recess because the channels 3367 provide a restricted space in which microbes can be trapped between the distal tip surface 3352 and an inside surface of a female luer. The apex 3364 of the blades 3363 provide a maximum outer diameter of the distal tip 3355, and the troughs 3368 of the channels 3367 provide a minimum outer diameter of the distal tip 3355. Although some fluid flow between adjacent channels 3367 is possible when the male luer 3341 is coupled with a female luer, the blades 3363 provide a partial physical barrier. As seen in
The male luer cap 3301 does not include a lumen, as it is designed to prevent fluid flow out of a medical device having a female luer at the proximal end of the medical device. An antimicrobial agent can coat the distal tip surface 3352. In some examples, the antimicrobial agent can also coat the end face 3304. Although not shown in the drawings of
Turning now to
The male luer 3441 comprises a tapered sealing member 3442. The tapered sealing member 3442 has a frustoconical shape that tapers from a larger outer diameter at the proximal portion of the tapered sealing member 3442 to a smaller outer diameter at the distal portion of the tapered sealing member near the tapered surface distal edge 3461. The tapered sealing member 3442 has a tapered sealing surface 3443 that is configured to mate with a female luer to create a fluid tight fit. The luer coupler 3401 further includes threads 3402 that allow the luer coupler 3401 to couple with a female connector.
The male luer 3441 includes a distal tip 3455 with an end face 3404. The distal tip 3455 of the male luer 3441 is recessed from the distal line of taper of the tapered sealing member 3442. A distal recess 3451 is formed by a recessed portion of the distal tip 3455. The distal tip surface 3452 of the distal tip 3455 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 3443.
The male luer 3441 includes a tapered surface distal edge 3461 that defines a proximal end of the distal tip 3455. In some examples, an antimicrobial agent is applied to the distal tip surface 3452 by coating, spraying, or dipping the distal tip 3455 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 3443. An antimicrobial agent on the distal tip surface 3452 of the distal tip 3455 kills microbes within the distal recess 3451 between the surface of the female luer and the distal tip surface 3452. The distal recess 3451 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 3452 so that microbes are exposed to a high antimicrobial concentration.
The male luer 3441 further includes multiple blades 3463 arrayed around the distal tip 3455 of the male luer 3441. Between the blades 3463 are a plurality of channels 3467. In the example of
During insertion of the male luer 3441 into a female luer, portions of the distal tip 3455 may come in contact with the inside surface of the female luer. The apex 3464 of each blade 3463 may come in contact with the female luer surface, but the troughs 3468 of the channels 3467 will not come in contact with the female luer surface. Thus, in comparison to the tapered surface distal edge 3461, the blades 3463 have a relatively smaller surface area near the end face 3404 of the distal tip 3455. This minimizes the amount of ingress of microbes that can be attributed to microbes being pushed into the body of the female luer by the male luer 3441.
The channels 3467 affect confinement of microbes within the distal recess because the channels 3467 provide a restricted space in which microbes can be trapped between the distal tip surface 3452 and an inside surface of a female luer. The apex 3464 of the blades 3463 provide a maximum outer diameter of the distal tip 3455, and the troughs 3468 of the channels 3467 provide a minimum outer diameter of the distal tip 3455. Although some fluid flow between adjacent channels 3467 is possible when the male luer 3441 is coupled with a female luer, the blades 3463 provide a partial physical barrier. As seen in
Turning now to
The male luer 3541 comprises a tapered sealing member 3542. The tapered sealing member 3542 has a frustoconical shape that tapers from a larger outer diameter at the proximal portion of the tapered sealing member 3542 to a smaller outer diameter at the distal portion of the tapered sealing member near the tapered surface distal edge 3561. The tapered sealing member 3542 has a tapered sealing surface 3543 that is configured to mate with a female luer to create a fluid tight fit. The luer coupler 3501 further includes threads 3502 that allow the luer coupler 3501 to couple with a female connector.
The male luer 3541 includes a distal tip 3555 with an end face 3504. The distal tip 3555 of the male luer 3541 is recessed from the distal line of taper of the tapered sealing member 3542. A distal recess 3551 is formed by a recessed portion of the distal tip 3555. The distal tip surface 3552 of the distal tip 3555 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 3543.
The male luer 3541 includes a tapered surface distal edge 3561 that defines a proximal end of the distal tip 3555. In some examples, an antimicrobial agent is applied to the distal tip surface 3552 by coating, spraying, or dipping the distal tip 3555 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 3543. An antimicrobial agent on the distal tip surface 3552 of the distal tip 3555 kills microbes within the distal recess 3551 between the surface of the female luer and the distal tip surface 3552. The distal recess 3551 is designed to confine the antimicrobial agent between the inner surface of a female luer and the distal tip surface 3552 so that microbes are exposed to a high antimicrobial concentration.
The tapered surface distal edge 3561 has a tapered surface distal edge face 3562. A proximal trap 3571 is defined between the distal tip surface 3552 and the proximal trap walls 3573. The proximal trap 3571 is a cavity that is bounded on multiple sides. The proximal trap 3571 opens on the distal recess 3551. The proximal trap is adjacent to the tapered surface distal edge face 3562. As will be discussed below in relation to
The proximal trap 3571 stores an antimicrobial agent within the annular cavity defined by the proximal trap 3571. In some examples, microbes reside near the interface between the tapered surface distal edge 3561 and a surface of a female luer. The antimicrobial agent stored in the proximal trap 3571 ensures that the concentration of the antimicrobial agent remains high (up to the level of saturation) in the vicinity of microbes.
Both the proximal trap 3571 and the distal recess 3551 are designed to minimize washout of the antimicrobial agent from the volume created between the female luer surface and the distal tip surface 3552. The proximal trap 3571 has no separate entrance and exit. The antimicrobial agent on the surface of the proximal trap wall 3573 will diffuse out of the proximal trap 3571 after the male luer 3541 has been installed inside a female luer. The proximal trap 3571 prevents or minimizes fluid flow within the volume of the proximal trap 3571 because there is no through path to the body of the female luer lumen. Therefore, the antimicrobial agent is not readily washed away from the proximal trap 3571.
As seen in
The luer coupler 3701 is similar to the luer coupler 3501, with similar features and functions. The male connector portion 3749 of the luer coupler 3501 is similar to the male connector 2001 described in connection with
The luer coupler 3701 includes a male connector portion 3749 and a female connector portion 3789 integral with the male connector portion 3749. A lumen 3712 runs through both the female connector portion 3789 and the male connector portion 3749. The female connector portion 3789 further includes a female luer tapered surface 3788.
The luer coupler 3701 includes a male luer 3741. The male luer 3741 comprises a tapered sealing member 3742 with a tapered surface distal edge 3761. The luer coupler 3701 further includes threads 3702 that allow the luer coupler 3701 to couple with a female connector. A lumen 3712 runs through the luer coupler 3701.
The male luer 3741 includes a distal tip 3755 with a distal recess 3751 and an end face 3704. The distal tip surface 3752 of the distal tip 3755 defines an outer diameter that is smaller than the outer diameter of the extension of the tapered sealing surface 3743. The distal recess 3751 forms a cavity once the male luer 3741 is installed into a female luer 3691.
The tapered surface distal edge 3761 defines a proximal end of the distal tip 3755. In some examples, an antimicrobial agent is applied to the distal tip surface 3752 by coating, spraying, or dipping the distal tip 3755 with an antimicrobial agent, although other methods of applying antimicrobial agent are contemplated and are within the scope of the technology. In some examples, antimicrobial agent is also applied to the tapered sealing surface 3743.
The male luer 3741 further includes multiple blades 3763 arrayed around the distal tip 3755 of the male luer 3741. Between the blades 3763 are a plurality of channels 3767.
The male luer 3541 has a distal recess 3551. The male luer 3541 includes a distal tip 3555 having a distal tip surface 3552. A cavity is formed between the distal tip surface 3552 and the tapered sealing surface 3688 of the female luer 3691. The cavity 3802 is also bounded by a tapered surface distal edge face 3562 adjacent to tapered surface distal edge 3561. In the example of
A fluid passage is defined within the lumen 3512 of the male luer 3541 and the lumen 3695 of the female luer 3691. The fluid passage has multiple fluid flow regions. A bulk flow region 3801 is the space in which fluid travels through the connection of the male and female luers. A cavity 3802 is formed between the distal tip surface 3552 and the female luer tapered sealing surface 3688. A boundary region 3803 is situated between the bulk flow region 3801 and the cavity 3802. A proximal trap region 3804 is situated proximal to the tapered surface distal edge face 3562.
The distal tip surface 3552 contains a solid deposit of an antimicrobial agent, referred to as the load. An antimicrobial composition can be deposited in the proximal trap 3571 and on one or more of the walls, surfaces or faces of the female connector. The distal tip surface 3552 can be the predominant location at which surface-bound microbes are present within the luer connection.
The cavity 3802 confines recirculation of fluids while a fluid load passes through the luer connection. The antimicrobial composition disperses into the fluidic recirculation. The recirculating fluid within the cavity 3802 recirculates the antimicrobial composition, which increases the antimicrobial concentration within this region and distributes the antimicrobial agent onto the inner surface of the female connector. The presence of antimicrobial agent along the inner surface of the female connector within the cavity 3802 prevents microbes located at the male-female interface from propagating along the wall of the female luer tapered sealing surface 3688.
Fluid flow through the design generates a set of three fluidic recirculations, or vortexes. These vortexes create a fluidic boundary between passing fluid and a microbial load located at the male-female interface edge. The three vortices can be described by their location. A proximal trap vortex contained in the proximal trap 3571 contains a large antimicrobial load. The cavity vortex is located adjacent to the proximal trap vortex. A boundary vortex is sandwiched between the cavity vortex and the stream of fluid passing through the bulk flow region 3801.
In the example of
In the example of
This application claims the benefit of U.S. Provisional Application No. 62/756,967, filed Nov. 7, 2018; U.S. patent application Ser. No. 16/404,378, filed May 6, 2019; U.S. patent application Ser. No. 16/444,486, filed Jun. 18, 2019; and U.S. patent application Ser. No. 16/447,671, filed Jun. 20, 2019, the contents of each of which are herein incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 382297 | Fry | May 1888 | A |
| 559697 | Tiugti et al. | May 1896 | A |
| 877946 | Overton | Feb 1908 | A |
| 975939 | William et al. | Nov 1910 | A |
| 1445642 | O'neill | Feb 1923 | A |
| 1793068 | Dickinson | Feb 1931 | A |
| 2098340 | Henahan | Nov 1937 | A |
| 2436297 | Guarnaschelli | Feb 1948 | A |
| 2457052 | Le Clair | Dec 1948 | A |
| 2771644 | Martin | Nov 1956 | A |
| 2842382 | Franck | Jul 1958 | A |
| 2968497 | Treleman | Jan 1961 | A |
| 3127892 | Bellamy, Jr. et al. | Apr 1964 | A |
| 3262448 | Ring et al. | Jul 1966 | A |
| 3270743 | Gingras | Sep 1966 | A |
| 3301392 | Eddingfield | Jan 1967 | A |
| 3304047 | Martin | Feb 1967 | A |
| 3334860 | Bolton, Jr. | Aug 1967 | A |
| 3411665 | Blum | Nov 1968 | A |
| 3484121 | Quinton | Dec 1969 | A |
| 3485416 | Fohrman | Dec 1969 | A |
| 3538950 | Porteners | Nov 1970 | A |
| 3595241 | Sheridan | Jul 1971 | A |
| 3604582 | Boudin | Sep 1971 | A |
| 3707972 | Villari et al. | Jan 1973 | A |
| 3729031 | Baldwin | Apr 1973 | A |
| 3882858 | Klemm | May 1975 | A |
| 3977401 | Pike | Aug 1976 | A |
| 3977517 | Kadlecik et al. | Aug 1976 | A |
| 3987930 | Fuson | Oct 1976 | A |
| 3993066 | Virag | Nov 1976 | A |
| 4041934 | Genese | Aug 1977 | A |
| 4046889 | Ondetti et al. | Sep 1977 | A |
| 4052511 | Cushman et al. | Oct 1977 | A |
| 4053052 | Jasper | Oct 1977 | A |
| 4053651 | Ondetti et al. | Oct 1977 | A |
| 4066067 | Micheli | Jan 1978 | A |
| 4076285 | Martinez | Feb 1978 | A |
| 4078686 | Karesh et al. | Mar 1978 | A |
| 4079738 | Dunn et al. | Mar 1978 | A |
| 4095810 | Kulle | Jun 1978 | A |
| 4113751 | Arnold | Sep 1978 | A |
| 4121585 | Becker, Jr. | Oct 1978 | A |
| 4129571 | Ondetti et al. | Dec 1978 | A |
| 4133441 | Mittleman et al. | Jan 1979 | A |
| 4143853 | Abramson | Mar 1979 | A |
| 4150845 | Kopacz et al. | Apr 1979 | A |
| 4154840 | Ondetti et al. | May 1979 | A |
| 4154960 | Ondetti et al. | May 1979 | A |
| 4192443 | McLaren | Mar 1980 | A |
| 4194509 | Pickering et al. | Mar 1980 | A |
| 4195632 | Parker et al. | Apr 1980 | A |
| 4233982 | Bauer et al. | Nov 1980 | A |
| 4243035 | Barrett | Jan 1981 | A |
| 4245635 | Kontos | Jan 1981 | A |
| 4264664 | Kunz | Apr 1981 | A |
| 4280632 | Yuhara | Jul 1981 | A |
| 4294370 | Toeppen | Oct 1981 | A |
| 4317446 | Ambrosio et al. | Mar 1982 | A |
| 4324239 | Gordon et al. | Apr 1982 | A |
| 4325368 | Kaemmerer | Apr 1982 | A |
| 4331783 | Stoy | May 1982 | A |
| 4334551 | Pfister | Jun 1982 | A |
| 4335756 | Sharp et al. | Jun 1982 | A |
| 4337327 | Stoy | Jun 1982 | A |
| 4340049 | Munsch | Jul 1982 | A |
| 4340052 | Dennehey et al. | Jul 1982 | A |
| 4354490 | Rogers | Oct 1982 | A |
| 4369294 | Stoy | Jan 1983 | A |
| 4370451 | Stoy | Jan 1983 | A |
| 4379458 | Bauer et al. | Apr 1983 | A |
| 4379874 | Stoy | Apr 1983 | A |
| 4384589 | Morris | May 1983 | A |
| 4387879 | Tauschinski | Jun 1983 | A |
| 4390016 | Riess | Jun 1983 | A |
| 4397442 | Larkin | Aug 1983 | A |
| 4402691 | Rosenthal et al. | Sep 1983 | A |
| 4405312 | Gross et al. | Sep 1983 | A |
| 4417890 | Dennehey et al. | Nov 1983 | A |
| 4420589 | Stoy | Dec 1983 | A |
| 4427126 | Ostrowsky | Jan 1984 | A |
| 4430073 | Bemis et al. | Feb 1984 | A |
| 4432764 | Lopez | Feb 1984 | A |
| 4432766 | Bellotti et al. | Feb 1984 | A |
| 4436125 | Blenkush | Mar 1984 | A |
| 4439179 | Lueders et al. | Mar 1984 | A |
| 4439184 | Wheeler | Mar 1984 | A |
| 4440207 | Genatempo et al. | Apr 1984 | A |
| 4444310 | Odell | Apr 1984 | A |
| 4446967 | Halkyard | May 1984 | A |
| 4447419 | Quadro | May 1984 | A |
| 4457749 | Bellotti et al. | Jul 1984 | A |
| 4461368 | Plourde | Jul 1984 | A |
| 4461896 | Portlock | Jul 1984 | A |
| 4480940 | Woodruff | Nov 1984 | A |
| 4507111 | Gordon et al. | Mar 1985 | A |
| 4511359 | Vaillancourt | Apr 1985 | A |
| 4534764 | Mittleman et al. | Aug 1985 | A |
| 4538836 | Kruetten | Sep 1985 | A |
| 4559043 | Whitehouse et al. | Dec 1985 | A |
| 4568675 | Bush et al. | Feb 1986 | A |
| 4585758 | Huang et al. | Apr 1986 | A |
| 4602042 | Chantler et al. | Jul 1986 | A |
| 4610469 | Wolff-Mooij | Sep 1986 | A |
| 4619640 | Potolsky et al. | Oct 1986 | A |
| 4623332 | Lindmayer et al. | Nov 1986 | A |
| 4624664 | Peluso et al. | Nov 1986 | A |
| 4626545 | Taub | Dec 1986 | A |
| 4629159 | Wellenstam | Dec 1986 | A |
| 4631188 | Stoy et al. | Dec 1986 | A |
| 4642091 | Richmond | Feb 1987 | A |
| 4660803 | Johnston et al. | Apr 1987 | A |
| 4662878 | Lindmayer | May 1987 | A |
| 4666057 | Come et al. | May 1987 | A |
| 4666427 | Larsson et al. | May 1987 | A |
| 4671306 | Spector | Jun 1987 | A |
| 4671412 | Gatten | Jun 1987 | A |
| 4681886 | Haugwitz et al. | Jul 1987 | A |
| 4692458 | Ryan et al. | Sep 1987 | A |
| 4692459 | Ryan et al. | Sep 1987 | A |
| 4700744 | Rutter et al. | Oct 1987 | A |
| 4703762 | Rathbone et al. | Nov 1987 | A |
| 4705790 | Hubele et al. | Nov 1987 | A |
| 4723603 | Plummer | Feb 1988 | A |
| 4728075 | Paradis | Mar 1988 | A |
| 4728321 | Chen | Mar 1988 | A |
| 4738668 | Bellotti et al. | Apr 1988 | A |
| 4745950 | Mathieu | May 1988 | A |
| 4747502 | Luenser | May 1988 | A |
| 4748160 | Bennion et al. | May 1988 | A |
| 4752983 | Grieshaber | Jun 1988 | A |
| 4769013 | Lorenz et al. | Sep 1988 | A |
| 4774964 | Bonaldo | Oct 1988 | A |
| 4774965 | Rodriguez et al. | Oct 1988 | A |
| 4778447 | Velde et al. | Oct 1988 | A |
| 4781702 | Herrli | Nov 1988 | A |
| 4799926 | Haber | Jan 1989 | A |
| 4804015 | Albinsson | Feb 1989 | A |
| 4808158 | Kreuzer et al. | Feb 1989 | A |
| 4810241 | Rogers | Mar 1989 | A |
| 4811847 | Reif et al. | Mar 1989 | A |
| 4813933 | Turner | Mar 1989 | A |
| 4816024 | Sitar et al. | Mar 1989 | A |
| 4834271 | Litwin | May 1989 | A |
| 4862913 | Wildfang | Sep 1989 | A |
| 4874366 | Zdeb et al. | Oct 1989 | A |
| 4883483 | Lindmayer | Nov 1989 | A |
| 4889255 | Schiemann et al. | Dec 1989 | A |
| 4894056 | Bommarito | Jan 1990 | A |
| 4898580 | Crowley | Feb 1990 | A |
| 4915687 | Sivert | Apr 1990 | A |
| 4917669 | Bonaldo | Apr 1990 | A |
| 4919658 | Badia | Apr 1990 | A |
| 4927019 | Haber et al. | May 1990 | A |
| 4935010 | Cox et al. | Jun 1990 | A |
| 4941873 | Fischer | Jul 1990 | A |
| 4950260 | Bonaldo | Aug 1990 | A |
| 4957637 | Cornell | Sep 1990 | A |
| 4963132 | Gibson | Oct 1990 | A |
| D313277 | Haining | Dec 1990 | S |
| D314050 | Sone | Jan 1991 | S |
| 4983161 | Dadson et al. | Jan 1991 | A |
| 4985017 | Theeuwes | Jan 1991 | A |
| 4989733 | Patry | Feb 1991 | A |
| 4991629 | Ernesto et al. | Feb 1991 | A |
| 4997371 | Fischer | Mar 1991 | A |
| 4999210 | Solomon et al. | Mar 1991 | A |
| 5002964 | Loscalzo | Mar 1991 | A |
| 5006114 | Rogers et al. | Apr 1991 | A |
| 5015238 | Solomon et al. | May 1991 | A |
| 5019096 | Fox, Jr. et al. | May 1991 | A |
| 5021059 | Kensey et al. | Jun 1991 | A |
| 5024657 | Needham et al. | Jun 1991 | A |
| 5025001 | Loscalzo et al. | Jun 1991 | A |
| 5026359 | Burroughs | Jun 1991 | A |
| 5031622 | LaHaye | Jul 1991 | A |
| 5033961 | Kandler et al. | Jul 1991 | A |
| 5047021 | Utterberg | Sep 1991 | A |
| 5049139 | Gilchrist | Sep 1991 | A |
| 5059186 | Yamamoto et al. | Oct 1991 | A |
| 5065783 | Ogle, II | Nov 1991 | A |
| 5070885 | Bonaldo | Dec 1991 | A |
| 5071411 | Hillstead | Dec 1991 | A |
| 5071413 | Utterberg | Dec 1991 | A |
| 5098385 | Walsh | Mar 1992 | A |
| 5108376 | Bonaldo | Apr 1992 | A |
| 5122123 | Vaillancourt | Jun 1992 | A |
| 5127626 | Hilal et al. | Jul 1992 | A |
| 5129824 | Keller | Jul 1992 | A |
| 5139483 | Ryan | Aug 1992 | A |
| 5143104 | Iba et al. | Sep 1992 | A |
| 5147333 | Raines | Sep 1992 | A |
| 5154703 | Bonaldo | Oct 1992 | A |
| 5154920 | Flesher et al. | Oct 1992 | A |
| 5184742 | DeCaprio et al. | Feb 1993 | A |
| 5190534 | Kendell | Mar 1993 | A |
| 5195957 | Tollini | Mar 1993 | A |
| RE34223 | Bonaldo | Apr 1993 | E |
| 5199948 | McPhee | Apr 1993 | A |
| 5201725 | Kling | Apr 1993 | A |
| 5203775 | Frank et al. | Apr 1993 | A |
| 5205820 | Kriesel | Apr 1993 | A |
| 5205821 | Kruger et al. | Apr 1993 | A |
| 5207706 | Menaker | May 1993 | A |
| 5211634 | Vaillancourt | May 1993 | A |
| 5212204 | Keefer et al. | May 1993 | A |
| 5215537 | Lynn et al. | Jun 1993 | A |
| 5240675 | Wilk et al. | Aug 1993 | A |
| 5242421 | Chan | Sep 1993 | A |
| 5242425 | White et al. | Sep 1993 | A |
| 5246011 | Caillouette | Sep 1993 | A |
| 5250550 | Keefer et al. | Oct 1993 | A |
| 5251873 | Atkinson et al. | Oct 1993 | A |
| D342134 | Mongeon | Dec 1993 | S |
| 5269771 | Thomas et al. | Dec 1993 | A |
| 5278192 | Fung et al. | Jan 1994 | A |
| 5281206 | Lopez | Jan 1994 | A |
| 5284475 | Mackal | Feb 1994 | A |
| 5295657 | Atkinson | Mar 1994 | A |
| 5297310 | Cox et al. | Mar 1994 | A |
| 5301686 | Newman | Apr 1994 | A |
| 5304130 | Button | Apr 1994 | A |
| 5306243 | Bonaldo | Apr 1994 | A |
| 5312377 | Dalton | May 1994 | A |
| 5324270 | Kayan et al. | Jun 1994 | A |
| 5324647 | Rubens et al. | Jun 1994 | A |
| 5330235 | Wagner et al. | Jul 1994 | A |
| 5330426 | Kriesel et al. | Jul 1994 | A |
| 5330450 | Lopez | Jul 1994 | A |
| 5330899 | Devaughn et al. | Jul 1994 | A |
| 5337730 | Maguire | Aug 1994 | A |
| 5344414 | Lopez et al. | Sep 1994 | A |
| 5352410 | Hansen et al. | Oct 1994 | A |
| 5354267 | Niermann et al. | Oct 1994 | A |
| 5356396 | Wyatt et al. | Oct 1994 | A |
| 5360413 | Leason et al. | Nov 1994 | A |
| 5366505 | Farber | Nov 1994 | A |
| 5366997 | Keefer et al. | Nov 1994 | A |
| 5370614 | Amundson et al. | Dec 1994 | A |
| 5370636 | Von Witzleben | Dec 1994 | A |
| 5370640 | Kolff | Dec 1994 | A |
| 5375589 | Bhatta | Dec 1994 | A |
| 5380306 | Brinon | Jan 1995 | A |
| 5380758 | Stamler et al. | Jan 1995 | A |
| 5391150 | Richmond | Feb 1995 | A |
| 5402826 | Molnar et al. | Apr 1995 | A |
| 5405331 | Behnke et al. | Apr 1995 | A |
| 5405333 | Richmond | Apr 1995 | A |
| 5405919 | Keefer et al. | Apr 1995 | A |
| 5407807 | Markus | Apr 1995 | A |
| 5409012 | Sahatjian | Apr 1995 | A |
| 5411499 | Dudar et al. | May 1995 | A |
| 5417673 | Gordon | May 1995 | A |
| 5425465 | Healy | Jun 1995 | A |
| 5428070 | Cooke et al. | Jun 1995 | A |
| 5433330 | Yatsko et al. | Jul 1995 | A |
| 5433705 | Giebel et al. | Jul 1995 | A |
| 5439451 | Collinson et al. | Aug 1995 | A |
| 5441487 | Vedder | Aug 1995 | A |
| 5445623 | Richmond | Aug 1995 | A |
| 5456668 | Ogle, II | Oct 1995 | A |
| 5456675 | Wolbring et al. | Oct 1995 | A |
| 5464399 | Boettger | Nov 1995 | A |
| 5470307 | Lindall | Nov 1995 | A |
| 5470327 | Helgren et al. | Nov 1995 | A |
| 5471706 | Wallock et al. | Dec 1995 | A |
| 5474536 | Bonaldo | Dec 1995 | A |
| 5480393 | Bommarito | Jan 1996 | A |
| 5492147 | Challender et al. | Feb 1996 | A |
| 5496288 | Sweeney | Mar 1996 | A |
| 5501426 | Atkinson et al. | Mar 1996 | A |
| 5507733 | Larkin et al. | Apr 1996 | A |
| 5507744 | Tay et al. | Apr 1996 | A |
| 5514177 | Kurz et al. | May 1996 | A |
| 5518026 | Benjey | May 1996 | A |
| 5520665 | Fleetwood | May 1996 | A |
| 5520666 | Choudhury et al. | May 1996 | A |
| 5485827 | Zapol et al. | Jun 1996 | A |
| 5525357 | Keefer et al. | Jun 1996 | A |
| 5531695 | Swisher | Jul 1996 | A |
| 5533708 | Atkinson et al. | Jul 1996 | A |
| 5533983 | Haining | Jul 1996 | A |
| 5535785 | Werge et al. | Jul 1996 | A |
| 5536241 | Zapol | Jul 1996 | A |
| 5536258 | Folden | Jul 1996 | A |
| 5540661 | Tomisaka et al. | Jul 1996 | A |
| 5545614 | Stamler et al. | Aug 1996 | A |
| 5549566 | Elias et al. | Aug 1996 | A |
| 5549651 | Lynn | Aug 1996 | A |
| 5552115 | Malchesky | Sep 1996 | A |
| 5552118 | Mayer | Sep 1996 | A |
| 5554127 | Crouther et al. | Sep 1996 | A |
| 5554135 | Menyhay | Sep 1996 | A |
| 5555908 | Edwards et al. | Sep 1996 | A |
| 5569235 | Ross et al. | Oct 1996 | A |
| 5573516 | Tyner | Nov 1996 | A |
| 5575769 | Vaillancourt | Nov 1996 | A |
| 5578059 | Patzer | Nov 1996 | A |
| 5580530 | Kowatsch et al. | Dec 1996 | A |
| 5584819 | Kopfer | Dec 1996 | A |
| 5591137 | Stevens | Jan 1997 | A |
| 5591143 | Trombley, III et al. | Jan 1997 | A |
| 5597536 | Mayer | Jan 1997 | A |
| 5599352 | Dinh et al. | Feb 1997 | A |
| 5605696 | Eury et al. | Feb 1997 | A |
| 5607072 | Rigney et al. | Mar 1997 | A |
| 5613615 | Zeyfang et al. | Mar 1997 | A |
| 5616130 | Mayer | Apr 1997 | A |
| 5620088 | Martin et al. | Apr 1997 | A |
| 5620427 | Werschmidt et al. | Apr 1997 | A |
| 5624402 | Imbert | Apr 1997 | A |
| 5628733 | Zinreich et al. | May 1997 | A |
| RE35539 | Bonaldo | Jun 1997 | E |
| 5645538 | Richmond | Jul 1997 | A |
| 5665077 | Resen et al. | Sep 1997 | A |
| 5674206 | Allton et al. | Oct 1997 | A |
| 5676346 | Leinsing | Oct 1997 | A |
| 5685866 | Lopez | Nov 1997 | A |
| 5685868 | Lundquist | Nov 1997 | A |
| 5688253 | Lundquist | Nov 1997 | A |
| 5694978 | Heilmann et al. | Dec 1997 | A |
| 5699821 | Paradis | Dec 1997 | A |
| 5700248 | Lopez | Dec 1997 | A |
| 5702017 | Goncalves | Dec 1997 | A |
| 5716339 | Tanaka et al. | Feb 1998 | A |
| 5722537 | Sigler | Mar 1998 | A |
| 5735826 | Richmond | Apr 1998 | A |
| 5738144 | Rogers | Apr 1998 | A |
| 5743892 | Loh et al. | Apr 1998 | A |
| 5749861 | Guala et al. | May 1998 | A |
| 5763409 | Bayol et al. | Jun 1998 | A |
| 5770645 | Stamler et al. | Jun 1998 | A |
| 5776116 | Lopez | Jul 1998 | A |
| 5782808 | Folden | Jul 1998 | A |
| 5782816 | Werschmidt et al. | Jul 1998 | A |
| 5785693 | Haining | Jul 1998 | A |
| 5792120 | Menyhay | Aug 1998 | A |
| 5797887 | Rosen et al. | Aug 1998 | A |
| 5806831 | Paradis | Sep 1998 | A |
| 5810792 | Fangrow, Jr. et al. | Sep 1998 | A |
| 5814024 | Thompson et al. | Sep 1998 | A |
| 5814666 | Green et al. | Sep 1998 | A |
| 5820601 | Mayer | Oct 1998 | A |
| 5820604 | Fox et al. | Oct 1998 | A |
| 5827244 | Boettger | Oct 1998 | A |
| 5839715 | Leinsing | Nov 1998 | A |
| 5848994 | Richmond | Dec 1998 | A |
| 5902631 | Wang et al. | May 1999 | A |
| 5941857 | Nguyen et al. | Aug 1999 | A |
| 5947954 | Bonaldo | Sep 1999 | A |
| 5951519 | Utterberg | Sep 1999 | A |
| 5954957 | Chin-Loy et al. | Sep 1999 | A |
| 5971972 | Rosenbaum | Oct 1999 | A |
| D416086 | Parris et al. | Nov 1999 | S |
| 5989229 | Chiappetta | Nov 1999 | A |
| 5994444 | Trescony | Nov 1999 | A |
| 6029946 | Doyle | Feb 2000 | A |
| 6036171 | Weinheimer et al. | Mar 2000 | A |
| 6041805 | Gydesen et al. | Mar 2000 | A |
| 6045539 | Menyhay | Apr 2000 | A |
| 6045623 | Cannon | Apr 2000 | A |
| 6050978 | Orr et al. | Apr 2000 | A |
| 6059107 | NØsted et al. | May 2000 | A |
| 6063062 | Paradis | May 2000 | A |
| 6068011 | Paradis | May 2000 | A |
| 6068475 | Stoyka, Jr. et al. | May 2000 | A |
| 6068617 | Richmond | May 2000 | A |
| 6071413 | Dyke | Jun 2000 | A |
| 6079432 | Paradis | Jun 2000 | A |
| 6087479 | Stamler et al. | Jul 2000 | A |
| 6093743 | Lai et al. | Jul 2000 | A |
| 6095356 | Rits | Aug 2000 | A |
| 6099519 | Olsen et al. | Aug 2000 | A |
| 6105812 | Riordan | Aug 2000 | A |
| 6106502 | Richmond | Aug 2000 | A |
| 6113068 | Ryan | Sep 2000 | A |
| 6113572 | Gailey et al. | Sep 2000 | A |
| 6116468 | Nilson | Sep 2000 | A |
| 6117114 | Paradis | Sep 2000 | A |
| 6126640 | Tucker et al. | Oct 2000 | A |
| 6142446 | Leinsing | Nov 2000 | A |
| 6143318 | Gilchrist et al. | Nov 2000 | A |
| 6146363 | Giebel et al. | Nov 2000 | A |
| 6152913 | Feith et al. | Nov 2000 | A |
| 6158614 | Haines et al. | Dec 2000 | A |
| 6170522 | Tanida | Jan 2001 | B1 |
| 6171287 | Lynn et al. | Jan 2001 | B1 |
| 6174539 | Stamler et al. | Jan 2001 | B1 |
| 6179141 | Nakamura | Jan 2001 | B1 |
| 6183450 | Lois | Feb 2001 | B1 |
| 6202870 | Pearce | Mar 2001 | B1 |
| 6202901 | Gerber et al. | Mar 2001 | B1 |
| 6206134 | Stark et al. | Mar 2001 | B1 |
| 6206860 | Richmond | Mar 2001 | B1 |
| 6207855 | Toone et al. | Mar 2001 | B1 |
| 6217564 | Peters et al. | Apr 2001 | B1 |
| 6227391 | King | May 2001 | B1 |
| 6232406 | Stoy | May 2001 | B1 |
| 6232434 | Stamler et al. | May 2001 | B1 |
| 6237800 | Barrett et al. | May 2001 | B1 |
| 6242393 | Ishida et al. | Jun 2001 | B1 |
| 6245048 | Fangrow et al. | Jun 2001 | B1 |
| 6245056 | Walker et al. | Jun 2001 | B1 |
| 6248380 | Kocher et al. | Jun 2001 | B1 |
| 6250315 | Ernster | Jun 2001 | B1 |
| 6255277 | Stamler et al. | Jul 2001 | B1 |
| 6267754 | Peters | Jul 2001 | B1 |
| 6299132 | Weinheimer et al. | Oct 2001 | B1 |
| 6315113 | Britton et al. | Nov 2001 | B1 |
| 6315761 | Shcherbina et al. | Nov 2001 | B1 |
| 6359167 | Toone et al. | Mar 2002 | B2 |
| 6359182 | Stamler et al. | Mar 2002 | B1 |
| 6375231 | Picha et al. | Apr 2002 | B1 |
| 6379660 | Saavedra et al. | Apr 2002 | B1 |
| 6379691 | Tedeschi et al. | Apr 2002 | B1 |
| 6394983 | Mayoral et al. | May 2002 | B1 |
| 6402207 | Segal et al. | Jun 2002 | B1 |
| 6403759 | Stamler et al. | Jun 2002 | B2 |
| 6409716 | Sahatjian et al. | Jun 2002 | B1 |
| 6428520 | Lopez | Aug 2002 | B1 |
| 6431219 | Redler et al. | Aug 2002 | B1 |
| 6444318 | Guire et al. | Sep 2002 | B1 |
| 6468259 | Djokic et al. | Oct 2002 | B1 |
| 6471978 | Stamler et al. | Oct 2002 | B1 |
| 6488951 | Toone et al. | Dec 2002 | B2 |
| 6491965 | Berry et al. | Dec 2002 | B1 |
| 6499719 | Clancy et al. | Dec 2002 | B1 |
| 6508792 | Szames et al. | Jan 2003 | B2 |
| 6508807 | Peters | Jan 2003 | B1 |
| 6538116 | Stamler et al. | Mar 2003 | B2 |
| 6541802 | Doyle | Apr 2003 | B2 |
| 6543745 | Enerson | Apr 2003 | B1 |
| 6550493 | Williamson et al. | Apr 2003 | B2 |
| 6555504 | Ayai et al. | Apr 2003 | B1 |
| 6562781 | Berry et al. | May 2003 | B1 |
| 6581906 | Pott et al. | Jun 2003 | B2 |
| 6583311 | Toone et al. | Jun 2003 | B2 |
| 6585691 | Vitello | Jul 2003 | B1 |
| 6595964 | Finley et al. | Jul 2003 | B2 |
| 6595981 | Huet | Jul 2003 | B2 |
| 6605294 | Sawhney | Aug 2003 | B2 |
| 6605751 | Gibbins et al. | Aug 2003 | B1 |
| 6609696 | Enerson | Aug 2003 | B2 |
| 6632199 | Tucker et al. | Oct 2003 | B1 |
| 6634498 | KayerØd et al. | Oct 2003 | B2 |
| 6656217 | Herzog, Jr. et al. | Dec 2003 | B1 |
| 6666852 | Niedospial, Jr. | Dec 2003 | B2 |
| 6673891 | Stamler et al. | Jan 2004 | B2 |
| 6679395 | Pfefferkorn et al. | Jan 2004 | B1 |
| 6679870 | Finch et al. | Jan 2004 | B1 |
| 6681803 | Taneya et al. | Jan 2004 | B2 |
| 6685694 | Finch et al. | Feb 2004 | B2 |
| 6692468 | Waldenburg | Feb 2004 | B1 |
| 6695817 | Fangrow | Feb 2004 | B1 |
| 6716396 | Anderson | Apr 2004 | B1 |
| 6722705 | Korkor | Apr 2004 | B2 |
| 6725492 | Moore et al. | Apr 2004 | B2 |
| 6745998 | Doyle | Jun 2004 | B2 |
| 6786884 | DeCant, Jr. et al. | Sep 2004 | B1 |
| 6808510 | DiFiore | Oct 2004 | B1 |
| 6827766 | Carnes et al. | Dec 2004 | B2 |
| 6840501 | Doyle | Jan 2005 | B2 |
| 6871087 | Hughes et al. | Mar 2005 | B1 |
| 6875205 | Leinsing | Apr 2005 | B2 |
| 6875840 | Stamler et al. | Apr 2005 | B2 |
| 6887994 | Stamler et al. | May 2005 | B2 |
| 6899315 | Mailville et al. | May 2005 | B2 |
| 6911025 | Miyahar | Jun 2005 | B2 |
| 6916051 | Fisher | Jul 2005 | B2 |
| 6929005 | Sullivan et al. | Aug 2005 | B2 |
| 6943035 | Davies et al. | Sep 2005 | B1 |
| 6955669 | Curutcharry | Oct 2005 | B2 |
| 6964406 | Doyle | Nov 2005 | B2 |
| 7004934 | Vaillancourt | Feb 2006 | B2 |
| 7015347 | Toone et al. | Mar 2006 | B2 |
| 7030238 | Stamler et al. | Apr 2006 | B2 |
| 7037302 | Vaillancourt | May 2006 | B2 |
| 7040598 | Raybuck | May 2006 | B2 |
| 7044441 | Doyle | May 2006 | B2 |
| 7045585 | Berry et al. | May 2006 | B2 |
| 7049308 | Stamler et al. | May 2006 | B2 |
| 7052711 | West et al. | May 2006 | B2 |
| 7056308 | Utterberg | Jun 2006 | B2 |
| 7067659 | Stamler et al. | Jun 2006 | B2 |
| 7081109 | Tighe et al. | Jul 2006 | B2 |
| 7083605 | Miyahara | Aug 2006 | B2 |
| 7087709 | Stamler et al. | Aug 2006 | B2 |
| 7097850 | Chappa et al. | Aug 2006 | B2 |
| 7100891 | Doyle | Sep 2006 | B2 |
| 7125396 | Leinsing et al. | Oct 2006 | B2 |
| 7140592 | Phillips | Nov 2006 | B2 |
| 7147625 | Sarangapani et al. | Dec 2006 | B2 |
| 7160272 | Eyal et al. | Jan 2007 | B1 |
| 7182313 | Doyle | Feb 2007 | B2 |
| 7195615 | Tan | Mar 2007 | B2 |
| 7198611 | Connell et al. | Apr 2007 | B2 |
| 7244249 | Leinsing et al. | Jul 2007 | B2 |
| 7259250 | Stamler et al. | Aug 2007 | B2 |
| 7279176 | West et al. | Oct 2007 | B1 |
| 7282186 | Lake, Jr. et al. | Oct 2007 | B2 |
| 7306197 | Parrino et al. | Dec 2007 | B2 |
| 7306198 | Doyle | Dec 2007 | B2 |
| 7306566 | Raybuck | Dec 2007 | B2 |
| 7309326 | Fangrow, Jr. | Dec 2007 | B2 |
| 7316669 | Ranalletta | Jan 2008 | B2 |
| 7347458 | Rome et al. | Mar 2008 | B2 |
| 7347853 | DiFiore et al. | Mar 2008 | B2 |
| 7350764 | Raybuck | Apr 2008 | B2 |
| 7361164 | Simpson et al. | Apr 2008 | B2 |
| 7417109 | Stamler et al. | Aug 2008 | B2 |
| 7431712 | Kim | Oct 2008 | B2 |
| 7442402 | Chudzik et al. | Oct 2008 | B2 |
| 7452349 | Miyahar | Nov 2008 | B2 |
| 7485107 | DiFiore et al. | Feb 2009 | B2 |
| 7491192 | DiFiore | Feb 2009 | B2 |
| 7497484 | Ziman | Mar 2009 | B2 |
| 7516846 | Hansen | Apr 2009 | B2 |
| 7588563 | Guala | Sep 2009 | B2 |
| 7611505 | Ranalletta et al. | Nov 2009 | B2 |
| 7614426 | Kitani et al. | Nov 2009 | B2 |
| 7615034 | DiFiore | Nov 2009 | B2 |
| 7625907 | Stamler et al. | Dec 2009 | B2 |
| 7635344 | Tennican et al. | Dec 2009 | B2 |
| D607325 | Rogers et al. | Jan 2010 | S |
| 7645274 | Whitley | Jan 2010 | B2 |
| 7651481 | Raybuck | Jan 2010 | B2 |
| 7666170 | Guala | Feb 2010 | B2 |
| 7708714 | Connell et al. | May 2010 | B2 |
| 7731678 | Tennican et al. | Jun 2010 | B2 |
| 7731679 | Tennican et al. | Jun 2010 | B2 |
| 7749189 | Tennican et al. | Jul 2010 | B2 |
| 7753891 | Tennican et al. | Jul 2010 | B2 |
| 7758530 | DiFiore et al. | Jul 2010 | B2 |
| 7758566 | Simpson et al. | Jul 2010 | B2 |
| 7762524 | Cawthon et al. | Jul 2010 | B2 |
| 7763006 | Tennican | Jul 2010 | B2 |
| 7766182 | Trent et al. | Aug 2010 | B2 |
| 7766897 | Ramsey et al. | Aug 2010 | B2 |
| 7776011 | Tennican et al. | Aug 2010 | B2 |
| 7780794 | Rogers et al. | Aug 2010 | B2 |
| 7785616 | Stamler et al. | Aug 2010 | B2 |
| 7794675 | Lynn | Sep 2010 | B2 |
| 7799010 | Tennican | Sep 2010 | B2 |
| 7803139 | Fangrow, Jr. | Sep 2010 | B2 |
| 7803140 | Fangrow, Jr. | Sep 2010 | B2 |
| 7815614 | Fangrow, Jr. | Oct 2010 | B2 |
| 7857793 | Raulerson et al. | Dec 2010 | B2 |
| 7922701 | Buchman | Apr 2011 | B2 |
| 7922711 | Ranalletta et al. | Apr 2011 | B2 |
| 7928079 | Hrabie et al. | Apr 2011 | B2 |
| 7938795 | DiFiore et al. | May 2011 | B2 |
| 7956062 | Stamler et al. | Jun 2011 | B2 |
| 7959026 | Bertani | Jun 2011 | B2 |
| 7963565 | Suter | Jun 2011 | B2 |
| 7972137 | Rosen | Jul 2011 | B2 |
| 7972322 | Tennican | Jul 2011 | B2 |
| 7981090 | Plishka et al. | Jul 2011 | B2 |
| 7985302 | Rogers et al. | Jul 2011 | B2 |
| 7993309 | Schweikert | Aug 2011 | B2 |
| 7998134 | Fangrow et al. | Aug 2011 | B2 |
| 8034454 | Terry | Oct 2011 | B2 |
| 8065773 | Vaillancourt et al. | Nov 2011 | B2 |
| 8066670 | Cluff et al. | Nov 2011 | B2 |
| 8069523 | Vaillancourt et al. | Dec 2011 | B2 |
| 8113837 | Zegarelli | Feb 2012 | B2 |
| 8146757 | Abreu et al. | Apr 2012 | B2 |
| 8162899 | Tennican | Apr 2012 | B2 |
| 8167847 | Anderson et al. | May 2012 | B2 |
| 8172825 | Solomon et al. | May 2012 | B2 |
| 8177761 | Howlett et al. | May 2012 | B2 |
| 8177772 | Christensen et al. | May 2012 | B2 |
| 8197749 | Howlett et al. | Jun 2012 | B2 |
| 8206514 | Rogers et al. | Jun 2012 | B2 |
| 8231587 | Solomon et al. | Jul 2012 | B2 |
| 8231602 | Anderson et al. | Jul 2012 | B2 |
| 8252247 | Ferlic | Aug 2012 | B2 |
| 8262628 | Fangrow, Jr. | Sep 2012 | B2 |
| 8262643 | Tennican | Sep 2012 | B2 |
| 8273303 | Ferlic et al. | Sep 2012 | B2 |
| 8281824 | Molema et al. | Oct 2012 | B2 |
| 8328767 | Solomon et al. | Dec 2012 | B2 |
| 8336152 | Kerr et al. | Dec 2012 | B2 |
| 8343112 | Solomon et al. | Jan 2013 | B2 |
| 8361408 | Lynn | Jan 2013 | B2 |
| 8372045 | Needle et al. | Feb 2013 | B2 |
| 8377040 | Burkholz et al. | Feb 2013 | B2 |
| 8414547 | DiFiore et al. | Apr 2013 | B2 |
| 8454579 | Fangrow, Jr. | Jun 2013 | B2 |
| 8480968 | Lynn | Jul 2013 | B2 |
| 8491546 | Hoang et al. | Jul 2013 | B2 |
| 8500717 | Becker | Aug 2013 | B2 |
| 8506527 | Carlyon | Aug 2013 | B2 |
| 8506538 | Chelak | Aug 2013 | B2 |
| 8523798 | DiFiore | Sep 2013 | B2 |
| 8523831 | Solomon et al. | Sep 2013 | B2 |
| 8533887 | Hirst | Sep 2013 | B2 |
| 8545479 | Kitani et al. | Oct 2013 | B2 |
| 8568371 | Slopes et al. | Oct 2013 | B2 |
| 8622995 | Ziebol et al. | Jan 2014 | B2 |
| 8622996 | Ziebol et al. | Jan 2014 | B2 |
| 8641684 | Utterberg et al. | Feb 2014 | B2 |
| 8647308 | Solomon et al. | Feb 2014 | B2 |
| 8647326 | Solomon et al. | Feb 2014 | B2 |
| 8651271 | Shen | Feb 2014 | B1 |
| 8740864 | Hoang et al. | Jun 2014 | B2 |
| 8758307 | Grimm et al. | Jun 2014 | B2 |
| 8777504 | Shaw et al. | Jul 2014 | B2 |
| 8791073 | West et al. | Jul 2014 | B2 |
| 8845593 | Anderson et al. | Sep 2014 | B2 |
| 8877231 | Rosen | Nov 2014 | B2 |
| 8910919 | Bonnal et al. | Dec 2014 | B2 |
| 8920404 | DiFiore et al. | Dec 2014 | B2 |
| 8968268 | Anderson et al. | Mar 2015 | B2 |
| 8981139 | Schoenfisch et al. | Mar 2015 | B2 |
| 8999073 | Rogers et al. | Apr 2015 | B2 |
| 9022984 | Ziebol et al. | May 2015 | B2 |
| 9072296 | Mills et al. | Jul 2015 | B2 |
| 9072868 | Ziebol et al. | Jul 2015 | B2 |
| 9078992 | Ziebol et al. | Jul 2015 | B2 |
| 9089680 | Ueda et al. | Jul 2015 | B2 |
| 9101685 | Li et al. | Aug 2015 | B2 |
| 9149624 | Lewis | Oct 2015 | B2 |
| 9192449 | Kerr et al. | Nov 2015 | B2 |
| 9205248 | Wu et al. | Dec 2015 | B2 |
| 9248093 | Kelley, III et al. | Feb 2016 | B2 |
| 9248229 | Devouassoux et al. | Feb 2016 | B2 |
| 9259284 | Rogers et al. | Feb 2016 | B2 |
| 9259535 | Anderson et al. | Feb 2016 | B2 |
| 9283367 | Hoang et al. | Mar 2016 | B2 |
| 9283368 | Hoang et al. | Mar 2016 | B2 |
| 9296525 | Murphy et al. | Mar 2016 | B2 |
| 9302049 | Tekeste | Apr 2016 | B2 |
| 9320858 | Grimm et al. | Apr 2016 | B2 |
| 9320859 | Grimm et al. | Apr 2016 | B2 |
| 9320860 | Grimm et al. | Apr 2016 | B2 |
| 9352080 | Goodall et al. | May 2016 | B2 |
| 9352142 | Ziebol et al. | May 2016 | B2 |
| 9381339 | Wu et al. | Jul 2016 | B2 |
| 9399125 | Burkholz | Jul 2016 | B2 |
| 9527660 | Tennican | Dec 2016 | B2 |
| 9592375 | Tennican | Mar 2017 | B2 |
| 9700676 | Anderson et al. | Jul 2017 | B2 |
| 9700677 | Anderson et al. | Jul 2017 | B2 |
| 9700710 | Anderson et al. | Jul 2017 | B2 |
| 9707348 | Anderson et al. | Jul 2017 | B2 |
| 9707349 | Anderson et al. | Jul 2017 | B2 |
| 9707350 | Anderson et al. | Jul 2017 | B2 |
| 9809355 | Solomon et al. | Nov 2017 | B2 |
| 9849276 | Ziebol et al. | Dec 2017 | B2 |
| 9867975 | Gardner et al. | Jan 2018 | B2 |
| 9907617 | Rogers | Mar 2018 | B2 |
| 9933094 | Fangrow | Apr 2018 | B2 |
| 9999471 | Rogers et al. | Jun 2018 | B2 |
| 10016587 | Gardner et al. | Jul 2018 | B2 |
| 10046156 | Gardner et al. | Aug 2018 | B2 |
| 10159829 | Ziebol et al. | Dec 2018 | B2 |
| 10166381 | Gardner et al. | Jan 2019 | B2 |
| 10195000 | Rogers et al. | Feb 2019 | B2 |
| 10201692 | Chang | Feb 2019 | B2 |
| 10328207 | Anderson et al. | Jun 2019 | B2 |
| 10525250 | Ziebol et al. | Jan 2020 | B1 |
| 10695550 | Gardner et al. | Jun 2020 | B2 |
| 10744316 | Fangrow | Aug 2020 | B2 |
| 10806919 | Gardner et al. | Oct 2020 | B2 |
| 10821278 | Gardner et al. | Nov 2020 | B2 |
| 11160932 | Anderson et al. | Nov 2021 | B2 |
| 20020077693 | Barclay et al. | Jun 2002 | A1 |
| 20020082682 | Barclay et al. | Jun 2002 | A1 |
| 20020098278 | Bates et al. | Jun 2002 | A1 |
| 20030039697 | Zhao et al. | Feb 2003 | A1 |
| 20030062376 | Sears et al. | Apr 2003 | A1 |
| 20030072783 | Stamler et al. | Apr 2003 | A1 |
| 20030153865 | Connell et al. | Aug 2003 | A1 |
| 20030199835 | Leinsing et al. | Oct 2003 | A1 |
| 20030208165 | Christensen et al. | Nov 2003 | A1 |
| 20040034042 | Tsuji et al. | Feb 2004 | A1 |
| 20040034329 | Mankus et al. | Feb 2004 | A1 |
| 20040037836 | Stamler et al. | Feb 2004 | A1 |
| 20040048542 | Thomaschefsky et al. | Mar 2004 | A1 |
| 20040052689 | Yao | Mar 2004 | A1 |
| 20040052831 | Modak et al. | Mar 2004 | A1 |
| 20040156908 | Polaschegg et al. | Aug 2004 | A1 |
| 20040210201 | Farnan | Oct 2004 | A1 |
| 20040215148 | Hwang et al. | Oct 2004 | A1 |
| 20040247640 | Zhao et al. | Dec 2004 | A1 |
| 20040249337 | DiFiore | Dec 2004 | A1 |
| 20040249338 | DeCant, Jr. et al. | Dec 2004 | A1 |
| 20040258560 | Lake, Jr. et al. | Dec 2004 | A1 |
| 20050013836 | Raad | Jan 2005 | A1 |
| 20050015075 | Wright et al. | Jan 2005 | A1 |
| 20050065479 | Schiller et al. | Mar 2005 | A1 |
| 20050098527 | Yates et al. | May 2005 | A1 |
| 20050124942 | Richmond | Jun 2005 | A1 |
| 20050124970 | Kunin et al. | Jun 2005 | A1 |
| 20050147524 | Bousquet | Jul 2005 | A1 |
| 20050147525 | Bousquet | Jul 2005 | A1 |
| 20050148930 | Hseih et al. | Jul 2005 | A1 |
| 20050152891 | Toone et al. | Jul 2005 | A1 |
| 20050171493 | Nicholls | Aug 2005 | A1 |
| 20050214185 | Castaneda | Sep 2005 | A1 |
| 20050220882 | Pritchard et al. | Oct 2005 | A1 |
| 20050228362 | Vaillancourt | Oct 2005 | A1 |
| 20050228482 | Herzog et al. | Oct 2005 | A1 |
| 20050256461 | DiFiore et al. | Nov 2005 | A1 |
| 20050265958 | West et al. | Dec 2005 | A1 |
| 20050267421 | Wing | Dec 2005 | A1 |
| 20050271711 | Lynch et al. | Dec 2005 | A1 |
| 20050288551 | Callister et al. | Dec 2005 | A1 |
| 20060004316 | DiFiore et al. | Jan 2006 | A1 |
| 20060024372 | Utterberg et al. | Feb 2006 | A1 |
| 20060030827 | Raulerson et al. | Feb 2006 | A1 |
| 20060058734 | Phillips | Mar 2006 | A1 |
| 20060096348 | DiFiore | May 2006 | A1 |
| 20060118122 | Martens et al. | Jun 2006 | A1 |
| 20060129109 | Shaw et al. | Jun 2006 | A1 |
| 20060142730 | Proulx et al. | Jun 2006 | A1 |
| 20060149191 | DiFiore | Jul 2006 | A1 |
| 20060161115 | Fangrow | Jul 2006 | A1 |
| 20060195117 | Rucker et al. | Aug 2006 | A1 |
| 20060202146 | Doyle | Sep 2006 | A1 |
| 20060206178 | Kim | Sep 2006 | A1 |
| 20060253084 | Nordgren | Nov 2006 | A1 |
| 20060261076 | Anderson | Nov 2006 | A1 |
| 20070003603 | Karandikar et al. | Jan 2007 | A1 |
| 20070088292 | Fangrow | Apr 2007 | A1 |
| 20070088293 | Fangrow | Apr 2007 | A1 |
| 20070088294 | Fangrow | Apr 2007 | A1 |
| 20070106205 | Connell et al. | May 2007 | A1 |
| 20070112333 | Hoang et al. | May 2007 | A1 |
| 20070167910 | Tennican et al. | Jul 2007 | A1 |
| 20070179453 | Lim et al. | Aug 2007 | A1 |
| 20070187353 | Fox et al. | Aug 2007 | A1 |
| 20070202177 | Hoang | Aug 2007 | A1 |
| 20070212381 | DiFiore et al. | Sep 2007 | A1 |
| 20070231315 | Lichte et al. | Oct 2007 | A1 |
| 20070248676 | Stamler et al. | Oct 2007 | A1 |
| 20070249996 | Tennican et al. | Oct 2007 | A1 |
| 20070265578 | Tennican et al. | Nov 2007 | A1 |
| 20070282280 | Tennican | Dec 2007 | A1 |
| 20070287989 | Crawford et al. | Dec 2007 | A1 |
| 20080027399 | Harding et al. | Jan 2008 | A1 |
| 20080027401 | Ou-Yang | Jan 2008 | A1 |
| 20080033371 | Updegraff et al. | Feb 2008 | A1 |
| 20080039803 | Lynn | Feb 2008 | A1 |
| 20080058733 | Vogt et al. | Mar 2008 | A1 |
| 20080093245 | Periasamy et al. | Apr 2008 | A1 |
| 20080095680 | Steffens et al. | Apr 2008 | A1 |
| 20080097315 | Miner et al. | Apr 2008 | A1 |
| 20080097407 | Plishka | Apr 2008 | A1 |
| 20080103485 | Kruger | May 2008 | A1 |
| 20080287920 | Fangrow et al. | May 2008 | A1 |
| 20080014005 | Shirley | Jun 2008 | A1 |
| 20080128646 | Clawson | Jun 2008 | A1 |
| 20080132880 | Buchman | Jun 2008 | A1 |
| 20080147047 | Davis et al. | Jun 2008 | A1 |
| 20080161763 | Harding et al. | Jul 2008 | A1 |
| 20080172007 | Bousquet | Jul 2008 | A1 |
| 20080177250 | Howlett et al. | Jul 2008 | A1 |
| 20080187460 | Utterberg et al. | Aug 2008 | A1 |
| 20080188791 | DiFiore et al. | Aug 2008 | A1 |
| 20080190485 | Guala | Aug 2008 | A1 |
| 20080235888 | Vaillancourt et al. | Oct 2008 | A1 |
| 20080262465 | Zinger et al. | Oct 2008 | A1 |
| 20080318333 | Nielsen et al. | Dec 2008 | A1 |
| 20080319423 | Tanghoj et al. | Dec 2008 | A1 |
| 20090008393 | Howlett et al. | Jan 2009 | A1 |
| 20090012426 | Tennican | Jan 2009 | A1 |
| 20090024096 | Hai et al. | Jan 2009 | A1 |
| 20090028750 | Ryan | Jan 2009 | A1 |
| 20090062766 | Howlett et al. | Mar 2009 | A1 |
| 20090093757 | Tennican | Apr 2009 | A1 |
| 20090099529 | Anderson et al. | Apr 2009 | A1 |
| 20090126867 | Decant, Jr. et al. | May 2009 | A1 |
| 20090137969 | Colantonio et al. | May 2009 | A1 |
| 20090149820 | DiFiore | Jun 2009 | A1 |
| 20090163876 | Chebator et al. | Jun 2009 | A1 |
| 20090205151 | Fisher et al. | Aug 2009 | A1 |
| 20090205656 | Nishibayashi et al. | Aug 2009 | A1 |
| 20090247485 | Ahmed et al. | Oct 2009 | A1 |
| 20090259194 | Pinedjian et al. | Oct 2009 | A1 |
| 20090270832 | Vancaillie et al. | Oct 2009 | A1 |
| 20090293882 | Terry | Dec 2009 | A1 |
| 20100004510 | Kuroshima | Jan 2010 | A1 |
| 20100047123 | Solomon et al. | Feb 2010 | A1 |
| 20100049170 | Solomon et al. | Feb 2010 | A1 |
| 20100050351 | Colantonio et al. | Mar 2010 | A1 |
| 20100064456 | Ferlic | Mar 2010 | A1 |
| 20100074932 | Talsma | Mar 2010 | A1 |
| 20100106102 | Ziebol et al. | Apr 2010 | A1 |
| 20100106103 | Ziebol et al. | Apr 2010 | A1 |
| 20100137472 | Ou-Yang | Jun 2010 | A1 |
| 20100143427 | King et al. | Jun 2010 | A1 |
| 20100152670 | Low | Jun 2010 | A1 |
| 20100160894 | Julian et al. | Jun 2010 | A1 |
| 20100172794 | Ferlic et al. | Jul 2010 | A1 |
| 20100242993 | Hoang et al. | Sep 2010 | A1 |
| 20100253070 | Cheon et al. | Oct 2010 | A1 |
| 20100280805 | DiFiore | Nov 2010 | A1 |
| 20100292673 | Korogi et al. | Nov 2010 | A1 |
| 20100292674 | Jepson et al. | Nov 2010 | A1 |
| 20100306938 | Rogers et al. | Dec 2010 | A1 |
| 20100318040 | Kelley, III et al. | Dec 2010 | A1 |
| 20110030726 | Vaillancourt et al. | Feb 2011 | A1 |
| 20110044850 | Solomon et al. | Feb 2011 | A1 |
| 20110046564 | Zhong | Feb 2011 | A1 |
| 20110046603 | Felsovalyi et al. | Feb 2011 | A1 |
| 20110054440 | Lewis | Mar 2011 | A1 |
| 20110062703 | Lopez | Mar 2011 | A1 |
| 20110064512 | Shaw et al. | Mar 2011 | A1 |
| 20110071475 | Horvath et al. | Mar 2011 | A1 |
| 20110082431 | Burgess et al. | Apr 2011 | A1 |
| 20110175347 | Okiyama | Jul 2011 | A1 |
| 20110184338 | McKay | Jul 2011 | A1 |
| 20110184382 | Cady | Jul 2011 | A1 |
| 20110208128 | Wu et al. | Aug 2011 | A1 |
| 20110232020 | Rogers et al. | Sep 2011 | A1 |
| 20110265825 | Rogers et al. | Nov 2011 | A1 |
| 20110276031 | Hoang et al. | Nov 2011 | A1 |
| 20110277788 | Rogers et al. | Nov 2011 | A1 |
| 20110282302 | Lopez et al. | Nov 2011 | A1 |
| 20110290799 | Anderson et al. | Dec 2011 | A1 |
| 20110314619 | Schweikert | Dec 2011 | A1 |
| 20120022469 | Alpert et al. | Jan 2012 | A1 |
| 20120031904 | Kuhn et al. | Feb 2012 | A1 |
| 20120039764 | Solomon et al. | Feb 2012 | A1 |
| 20120083730 | Rush et al. | Apr 2012 | A1 |
| 20120083750 | Sansoucy | Apr 2012 | A1 |
| 20120157965 | Wotton et al. | Jun 2012 | A1 |
| 20120191029 | Hopf et al. | Jul 2012 | A1 |
| 20120195807 | Ferlic | Aug 2012 | A1 |
| 20120216359 | Rogers et al. | Aug 2012 | A1 |
| 20120216360 | Rogers et al. | Aug 2012 | A1 |
| 20120220955 | Maseda et al. | Aug 2012 | A1 |
| 20120283693 | Anderson et al. | Nov 2012 | A1 |
| 20120283696 | Cronenberg et al. | Nov 2012 | A1 |
| 20120296284 | Anderson et al. | Nov 2012 | A1 |
| 20120302968 | Tennican | Nov 2012 | A1 |
| 20120302970 | Tennican | Nov 2012 | A1 |
| 20120302997 | Gardner et al. | Nov 2012 | A1 |
| 20120315201 | Ferlic et al. | Dec 2012 | A1 |
| 20130006194 | Anderson et al. | Jan 2013 | A1 |
| 20130023828 | Anderson et al. | Jan 2013 | A1 |
| 20130030414 | Gardner et al. | Jan 2013 | A1 |
| 20130035667 | Anderson et al. | Feb 2013 | A1 |
| 20130039953 | Dudnyk et al. | Feb 2013 | A1 |
| 20130053751 | Holtham | Feb 2013 | A1 |
| 20130072908 | Solomon et al. | Mar 2013 | A1 |
| 20130072909 | Solomon et al. | Mar 2013 | A1 |
| 20130085313 | Fowler et al. | Apr 2013 | A1 |
| 20130085474 | Charles et al. | Apr 2013 | A1 |
| 20130098938 | Efthimiadis | Apr 2013 | A1 |
| 20130102950 | DiFiore | Apr 2013 | A1 |
| 20130123754 | Solomon et al. | May 2013 | A1 |
| 20130134161 | Fogel et al. | May 2013 | A1 |
| 20130138085 | Tennican | May 2013 | A1 |
| 20130144258 | Ziebol et al. | Jun 2013 | A1 |
| 20130150795 | Snow | Jun 2013 | A1 |
| 20130164189 | Hadden | Jun 2013 | A1 |
| 20130171030 | Ferlic et al. | Jul 2013 | A1 |
| 20130183635 | Wilhoit | Jul 2013 | A1 |
| 20130184679 | Ziebol et al. | Jul 2013 | A1 |
| 20130197485 | Gardner et al. | Aug 2013 | A1 |
| 20130204231 | Ziebol | Aug 2013 | A1 |
| 20130274686 | Ziebol et al. | Oct 2013 | A1 |
| 20140042116 | Shen et al. | Feb 2014 | A1 |
| 20140048079 | Gardner et al. | Feb 2014 | A1 |
| 20140052074 | Tekeste | Feb 2014 | A1 |
| 20140101876 | Rogers et al. | Apr 2014 | A1 |
| 20140155868 | Nelson et al. | Jun 2014 | A1 |
| 20140227144 | Liu et al. | Aug 2014 | A1 |
| 20140228775 | Burkholz | Aug 2014 | A1 |
| 20140243797 | Jensen et al. | Aug 2014 | A1 |
| 20150141934 | Gardner et al. | May 2015 | A1 |
| 20150148287 | Woo et al. | May 2015 | A1 |
| 20150217106 | Banik et al. | Aug 2015 | A1 |
| 20150258324 | Chida et al. | Sep 2015 | A1 |
| 20150306367 | DiFiore | Oct 2015 | A1 |
| 20150314119 | Anderson et al. | Nov 2015 | A1 |
| 20150320992 | Bonnet et al. | Nov 2015 | A1 |
| 20150343174 | Ziebol et al. | Dec 2015 | A1 |
| 20160001056 | Nelson et al. | Jan 2016 | A1 |
| 20160001058 | Ziebol et al. | Jan 2016 | A1 |
| 20160015863 | Gupta et al. | Jan 2016 | A1 |
| 20160045629 | Gardner et al. | Feb 2016 | A1 |
| 20160088995 | Ueda et al. | Mar 2016 | A1 |
| 20160089530 | Sathe | Mar 2016 | A1 |
| 20160101223 | Kelley, III et al. | Apr 2016 | A1 |
| 20160101276 | Tekeste | Apr 2016 | A1 |
| 20160106969 | Neftel | Apr 2016 | A1 |
| 20160158521 | Hoang et al. | Jun 2016 | A1 |
| 20160158522 | Hoang et al. | Jun 2016 | A1 |
| 20160213912 | Daneluzzi | Jul 2016 | A1 |
| 20160250420 | Maritan et al. | Sep 2016 | A1 |
| 20160354596 | DiFiore | Dec 2016 | A1 |
| 20170020911 | Berry et al. | Jan 2017 | A1 |
| 20170042636 | Young | Feb 2017 | A1 |
| 20170143447 | Rogers et al. | May 2017 | A1 |
| 20170182241 | DiFiore | Jun 2017 | A1 |
| 20170203092 | Ryan et al. | Jul 2017 | A1 |
| 20170239443 | Abitabilo et al. | Aug 2017 | A1 |
| 20180028403 | Fangrow | Feb 2018 | A1 |
| 20180200500 | Ziebol et al. | Jul 2018 | A1 |
| 20180214684 | Avula et al. | Aug 2018 | A1 |
| 20190201681 | Ziebol et al. | Jul 2019 | A1 |
| 20200069931 | Fangrow | Mar 2020 | A1 |
| 20200085690 | Fangrow | Mar 2020 | A1 |
| 20200121858 | Anderson | Apr 2020 | A1 |
| 20200139037 | Ziebol et al. | May 2020 | A1 |
| 20200139101 | Ziebol et al. | May 2020 | A1 |
| 20200139102 | Ziebol et al. | May 2020 | A1 |
| 20200139103 | Ziebol et al. | May 2020 | A1 |
| 20200155794 | Ziebol | May 2020 | A1 |
| 20200324102 | Fangrow | Oct 2020 | A1 |
| 20200330741 | Fangrow | Oct 2020 | A1 |
| 20200406020 | Fangrow | Dec 2020 | A1 |
| 20210162194 | Gardner | Jun 2021 | A1 |
| 20210205596 | Ziebol et al. | Jul 2021 | A1 |
| 20210308442 | Gardner | Oct 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 2013 3224680 | Sep 2016 | AU |
| 2 148 847 | Dec 1995 | CA |
| 2825217 | Mar 2007 | CA |
| 2 841 832 | Jun 2019 | CA |
| 2402327 | Oct 2000 | CN |
| 2815392 | Sep 2006 | CN |
| 201150420 | Nov 2008 | CN |
| 101405042 | Apr 2009 | CN |
| 201519335 | Jul 2010 | CN |
| 102202716 | Sep 2011 | CN |
| 102 844 073 | Dec 2012 | CN |
| 103796704 | Dec 2016 | CN |
| 106902402 | Jun 2017 | CN |
| 106902405 | Jun 2017 | CN |
| 3515665 | May 1986 | DE |
| 89 06 628 | Sep 1989 | DE |
| 43 34 272 | Apr 1995 | DE |
| 29617133 | Jan 1997 | DE |
| 0 088 341 | Sep 1983 | EP |
| 0 108 785 | May 1984 | EP |
| 0 174 162 | Mar 1986 | EP |
| 0 227 219 | Jul 1987 | EP |
| 0 237 239 | Sep 1987 | EP |
| 0 245 872 | Nov 1987 | EP |
| 0 257 485 | Mar 1988 | EP |
| 0 639 385 | Feb 1995 | EP |
| 0 734 721 | Oct 1996 | EP |
| 0 769 265 | Apr 1997 | EP |
| 1 061 000 | Oct 2000 | EP |
| 1 331 020 | Jul 2003 | EP |
| 1 471 011 | Oct 2004 | EP |
| 1442753 | Feb 2007 | EP |
| 1813293 | Aug 2007 | EP |
| 1 977 714 | Oct 2008 | EP |
| 1 312 008 | Apr 2009 | EP |
| 2 444117 | Apr 2012 | EP |
| 2 606 930 | Jun 2013 | EP |
| 2 671 604 | Dec 2013 | EP |
| 2 731 658 | May 2014 | EP |
| 2 493 149 | May 1982 | FR |
| 2 506 162 | Nov 1982 | FR |
| 2 782 910 | Mar 2000 | FR |
| 123221 | Feb 1919 | GB |
| 2 296 182 | Jun 1996 | GB |
| 2 333 097 | Jul 1999 | GB |
| 2 387 772 | Oct 2003 | GB |
| 57-131462 | Aug 1982 | JP |
| 04-99950 | Feb 1992 | JP |
| 09-216661 | Aug 1997 | JP |
| 2000-157630 | Jun 2000 | JP |
| 2002-234567 | Aug 2002 | JP |
| 2002-291906 | Oct 2002 | JP |
| 2005-218649 | Aug 2005 | JP |
| 2006-182663 | Jul 2006 | JP |
| 2011-036691 | Feb 2011 | JP |
| 2011-528647 | Nov 2011 | JP |
| 2013-520287 | Jun 2013 | JP |
| 2014-117461 | Jun 2014 | JP |
| 2 246 321 | Feb 2005 | RU |
| WO 8303975 | Nov 1983 | WO |
| WO 8505040 | Nov 1985 | WO |
| WO 9320806 | Oct 1993 | WO |
| WO 9507691 | Mar 1995 | WO |
| WO 9635416 | Nov 1996 | WO |
| WO 9638136 | Dec 1996 | WO |
| WO 199719701 | Jun 1997 | WO |
| WO 9812125 | Mar 1998 | WO |
| WO 199944665 | Sep 1999 | WO |
| WO 200170199 | Sep 2001 | WO |
| WO 200205188 | Jan 2002 | WO |
| WO 200247581 | Jun 2002 | WO |
| WO 200249544 | Jun 2002 | WO |
| WO 2003015677 | Feb 2003 | WO |
| WO 2003070296 | Aug 2003 | WO |
| WO 2004035129 | Apr 2004 | WO |
| WO 2004112846 | Dec 2004 | WO |
| WO 2005112954 | Dec 2005 | WO |
| WO 2005112974 | Dec 2005 | WO |
| WO 2006007690 | Jan 2006 | WO |
| WO 2006044236 | Apr 2006 | WO |
| 2006102756 | Oct 2006 | WO |
| WO 2007008511 | Jan 2007 | WO |
| WO 2007056773 | May 2007 | WO |
| WO 2007137056 | Nov 2007 | WO |
| WO 2008042285 | Apr 2008 | WO |
| WO 2008086631 | Jul 2008 | WO |
| WO 2008089196 | Jul 2008 | WO |
| WO 2008100950 | Aug 2008 | WO |
| WO 2008140807 | Nov 2008 | WO |
| WO 2009002474 | Dec 2008 | WO |
| WO 2009060322 | May 2009 | WO |
| WO 2009117135 | Sep 2009 | WO |
| WO 2009123709 | Oct 2009 | WO |
| WO 2009136957 | Nov 2009 | WO |
| WO 2009153224 | Dec 2009 | WO |
| WO 2010002757 | Jan 2010 | WO |
| WO 2010002808 | Jan 2010 | WO |
| WO 2010011616 | Jan 2010 | WO |
| WO 2010034470 | Apr 2010 | WO |
| WO 2010039171 | Apr 2010 | WO |
| 2010062589 | Jul 2010 | WO |
| WO 2011028722 | Mar 2011 | WO |
| WO 2011053924 | May 2011 | WO |
| WO 2011106374 | Sep 2011 | WO |
| WO 2011119021 | Sep 2011 | WO |
| WO 2012118829 | Sep 2012 | WO |
| WO 2012162006 | Nov 2012 | WO |
| 2013009998 | Jan 2013 | WO |
| WO 2013023146 | Feb 2013 | WO |
| WO 2012184716 | Dec 2013 | WO |
| WO 2013192574 | Dec 2013 | WO |
| WO 2014074929 | May 2014 | WO |
| WO 2014140949 | Sep 2014 | WO |
| WO 14159346 | Oct 2014 | WO |
| WO 2015074087 | May 2015 | WO |
| WO 2015119940 | Aug 2015 | WO |
| WO 2015120336 | Aug 2015 | WO |
| WO 2015164129 | Oct 2015 | WO |
| WO 2015168677 | Nov 2015 | WO |
| WO 2015174953 | Nov 2015 | WO |
| WO 2016025775 | Feb 2016 | WO |
| WO 2016182822 | Nov 2016 | WO |
| WO 2017015047 | Jan 2017 | WO |
| WO 2017127364 | Jul 2017 | WO |
| WO 2017127365 | Jul 2017 | WO |
| WO 2018009653 | Jan 2018 | WO |
| WO 2018071717 | Apr 2018 | WO |
| WO 2018204206 | Nov 2018 | WO |
| WO 2018237090 | Dec 2018 | WO |
| WO 2018237122 | Dec 2018 | WO |
| WO 2019178560 | Sep 2019 | WO |
| WO 2019246472 | Dec 2019 | WO |
| WO 2020097366 | May 2020 | WO |
| WO 2020251947 | Dec 2020 | WO |
| Entry |
|---|
| International Search Report and Written Opinion for PCT Application No. PCT/US2019/060319 dated Mar. 25, 2020 (13 pages). |
| Notice of Allowance for U.S. Appl. No. 16/404,378 dated Aug. 29, 2019 (8 pages). |
| “Small-bore connectors for liquids and gases in healthcare applications—Part 7: Connectors for intravascular or hypodermic applications,” ISO 80369-7, Corrected version dated Dec. 1, 2016 (50 pages). |
| “Non-Final Office Action,” for U.S. Appl. No. 16/404,378 dated Jul. 9, 2019 (20 pages). |
| “Response to Non-Final Rejection,” dated Jul. 9, 2019 for U.S. Appl. No. 16/404,378, submitted via EFS—Web on Jul. 12, 2019, 11 pages. |
| Antibiotic Lock Therapy Guidline, Standord Hospital and Clinics, Pharmacy Department Policies and Procedures, issued Jun. 2011. |
| Otto, Mosby's Pocket Guide to Infusion Therapy. Elsevier Health Sciences, 2004. pp. 65-66. Accessed at: http://books.google.com/books?id=j8T14HwWdS4C&Ipg=PP1&pg=PP1#v=onepage&f=false (Year: 2004). |
| “Small-bore connectors for liquids and gases in healthcare applications—Part : Connectors for intravascular or hypodermic applications,” ISO 80369-7, Corrected version dated Dec. 1, 2016 (50 pages). |
| Hospira, “You Work in Neverland,” Lifeshield Product Brochure in 2 pages, Published 2009. |
| Baxter Minicap: Photographs of the Baxter Minicap (Sep. 1, 1998) (4 pages). |
| Baxter, “Peritoneal Dialysis Patient Connectology,” Product Descriptions in 1 page, downloaded Jul. 1, 2011. |
| Beta Cap II Advertisement from Quinton Instrument Co. (Aug. 1981). |
| Catheter Connections, “Introducing DualCap,” Product Brochure in 1 page, Copyright 2011. |
| Charney, “Baxter Healthcare InterlinkTM IV Access System” in 1 page, from Handbook of Modern Hospital Safety. Published Mar. 1999. |
| Clave® Needlefree Connector, icumedical, human connections, 2 page brochure. 2012, M1-1065 Rev. 04. |
| Conical Fittings: International Standard, “Conical fittings with 6% (Luer) Taper for Syringes, Needles and certain Other Medical Equipment—Part 2: Lock Fittings”, Ref. No. ISO 594-2:1998. International Organization for Standardization (Sep. 1, 1998) 2nd ed. (16 pages). |
| Devine, redacted version of letter from David A. Divine, Esq. of Lee & Hayes, dated May 16, 2011 (3 pages). |
| Devine, redacted version of letter from David A. Divine, Esq. of Lee & Hayes, dated May 27, 2011 (3 pages). |
| Du. Y, et al. Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex, Journal of Biomedical Materials Research Part A, 2006, 216-225. |
| Holmer, E. et al. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor Xla, Factor Xlla and kallikrein by antithrombin, Biochem. J. (1981) 193, 395-400. |
| Hyprotek, “Port Protek,” Product Brochure in 1 page, downloaded Sep. 19, 2011 from http://www.hyprotek.com/products.html. |
| ICU Medical Antimicrobial Microclave, first sold Jan. 21, 2010, p. 1 -2. |
| Klement, P. et al. Chronic performance of polyurethane catheters covalently coated with ATH complex: A rabbit jugular vein model, Biomaterials, (2006), 27, 5107-5117. |
| Menyhay et al., “Disinfection of Needleless Catheter Connectors and Access Ports with Alcohol May Not Prevent Microbial Entry: The Promise of a Novel Antiseptic-Barrier Cap” Infection Control Hospital and Epidemiology, vol. 27, No. 1 (Jan. 2006) (5 pages). |
| Photographs of the Baxter Minicap (Sep. 1, 1998) (4 pages). |
| Quinton Beta Capp II advertisement, in 3 pages. |
| V-Link Luer Activated Device, with VitalShield Protective Coating, 2 page brochure, Baxter Dec. 2009. |
| U.S. Pat. No. 9,022,984, filed Oct. 26, 2009, Apparatus for Delivery of Device and Antimicrobial Agent Into Trans-Dermal Catheter. |
| U.S. Pat. No. 9,072,868, filed Oct. 26, 2009, Device for Delivery of Antimicrobial Agent Into Trans-Dermal Catheter. |
| U.S. Pat. No. 9,849,276, filed Jul. 12, 2012, Method of Delivering Antimicrobial to a Catheter. |
| U.S. Pat. No. 8,622,995, filed Jan. 28, 2013, Method for Delivery of Antimicrobial to Proximal End of Catheter. |
| U.S. Pat. No. 8,622,996, filed Mar. 15, 2013, Method for Applying Antimicrobial to Proximal End of Catheter. |
| U.S. Pat. No. 9,352,142, filed May 22, 2015, Method for Coating a Catheter With an Antimicrobial Agent. |
| U.S. Pat. No. 10,159,829, filed Jul. 7, 2015, Packaging Container for Antimicrobial Caps. |
| U.S. Appl. No. 16/227,651, filed Dec. 20, 2018, Packaging Container for Antimicrobial Caps. |
| U.S. Pat. No. 9,078,992, filed Jun. 11, 2013, Medical Device for Applying Antimicrobial to Proximal End of Catheter. |
| U.S. Appl. No. 16/691,242, filed Nov. 21, 2019, Antimicrobial Device Comprising a Cap With Ring and Insert. |
| U.S. Pat. No. 10,525,250, filed May 6, 2019, Infusion Device With Antimicrobial Properties. |
| U.S. Appl. No. 16/444,486, filed Jun. 18, 2019, Device for Delivering an Antimicrobial Composition Into an Infusion Device. |
| U.S. Appl. No. 16/447,671, filed Jun. 20, 2019, Needleless Connector With Antimicrobial Properties. |
| U.S. Appl. No. 16/553,704, filed Aug. 28, 2019, Peritoneal Dialysis Transfer Set With Antimicrobial Properties. |
| U.S. Appl. No. 16/558,921, filed Sep. 3, 2019, Syringe With Antimicrobial Properties. |
| U.S. Appl. No. 17/143,082, filed Jan. 6, 2021, Antimicrobial Cap for Luer Connector. |
| U.S. Appl. No. 15/726,838, filed Oct. 6, 2017, Medical Connectors Configured to Receive Emitters of Therapeutic Agents. |
| U.S. Appl. No. 16/694,564, filed Nov. 25, 2019, Medical Connectors Configured to Receive Emitters of Therapeutic Agents. |
| U.S. Appl. No. 16/717,199, filed Dec. 17, 2019, Priming Cap. |
| U.S. Appl. No. 16/340,300, filed Apr. 8, 2019, Sanitizing Caps for Medical Connectors. |
| U.S. Appl. No. 16/918,896, filed Jul. 1, 2020, Sanitizing Caps for Medical Connectors. |
| U.S. Appl. No. 16/669,303, filed Oct. 30, 2019, Medical Fluid Connectors and Methods for Providing Additives in Medical Fluid Lines. |
| U.S. Appl. No. 17/021,226, filed Sep. 15, 2020, Sanitizing Caps for Medical Connectors. |
| U.S. Appl. No. 17/125,515, filed Dec. 17, 2020, System for Sterilizing Intravenous Connectors and Tubing. |
| U.S. Appl. No. 11/821,290, filed Jun. 22, 2007, Antiseptic Cap and Antiseptic Cap Equipped Plunger and Syringe Barrel Assembly. |
| U.S. Appl. No. 13/456,853, filed Apr. 26, 2012, Antiseptic Cap. |
| U.S. Appl. No. 13/649,569, filed Oct. 11, 2012, Antiseptic Cap. |
| U.S. Appl. No. 12/214,526, filed Jun. 19, 2008, Antiseptic Cap With Thread Cover. |
| U.S. Appl. No. 13/095,516, filed Apr. 26, 2011, Method of Cleaning and Covering an Access Site. |
| U.S. Appl. No. 13/473,057, filed May 16, 2012, Antiseptic Cap With Antiseptic. |
| U.S. Appl. No. 13/560,499, filed Jul. 27, 2012, Method of Cleaning and Covering an Access Site. |
| U.S. Appl. No. 14/500,090, filed Sep. 29, 2014, Antiseptic Cap With Antiseptic. |
| U.S. Appl. No. 13/288,529, filed Nov. 3, 2011, Antiseptic Cap Equipped Syringe. |
| U.S. Appl. No. 13/547,650, filed Jul. 12, 2012, Antiseptic Cap Equipped Syringe. |
| U.S. Appl. No. 14/799,022, filed Jul. 14, 2015, Antiseptic Cap Equipped Syringe. |
| U.S. Appl. No. 15/637,998, filed Jun. 29, 2017, Antiseptic Cap. |
| U.S. Appl. No. 16/418,365, filed May 21, 2019, Antiseptic Cap. |
| U.S. Appl. No. 17/120,015, filed Dec. 11, 2020, Antiseptic Cap That Releases a Gas Such As Nitric Oxide. |
| U.S. Appl. No. 13/476,772, filed May 21, 2012, Caps for Needleless Connectors. |
| U.S. Appl. No. 16/016,960, filed Jun. 25, 2018, Caps for Needleless Connectors. |
| U.S. Appl. No. 16/882,210, filed May 22, 2020, Caps for Needleless Connectors. |
| U.S. Appl. No. 13/113,777, filed May 23, 2011, Antiseptic Line Cap. |
| U.S. Appl. No. 13/803,289, filed Mar. 14, 2013, Antiseptic Cap. |
| U.S. Appl. No. 16/162,106, filed Oct. 16, 2018, Antiseptic Cap. |
| U.S. Appl. No. 17/025,201, filed Sep. 18, 2020, Antiseptic Cap. |
| U.S. Appl. No. 13/968,151, filed Aug. 15, 2013, Disinfecting Mouth Guard for Vap Prevention. |
| U.S. Appl. No. 14/547,125, filed Nov. 18, 2014, Medicant Injection Device. |
| U.S. Appl. No. 14/554,018, filed Nov. 25, 2014, Catheter Lock Solution Formulations. |
| U.S. Appl. No. 14/616,593, filed Feb. 6, 2015, Swab Devices. |
| U.S. Appl. No. 14/703,134, filed May 4, 2015, Strip Package for Antiseptic Cap. |
| U.S. Appl. No. 16/102,597, filed Aug. 13, 2018, Strip Package for Antiseptic Cap. |
| U.S. Appl. No. 17/085,197, filed Oct. 30, 2020, Strip Package for Antiseptic Cap. |
| U.S. Appl. No. 14/826,180, filed Aug. 13, 2015, Disinfectant Caps. |
| Number | Date | Country | |
|---|---|---|---|
| 20200139104 A1 | May 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62756967 | Nov 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16404378 | May 2019 | US |
| Child | 16444486 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16447671 | Jun 2019 | US |
| Child | 16449180 | US | |
| Parent | 16444486 | Jun 2019 | US |
| Child | 16447671 | US |
